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CHAPTER 1: INTRODUCTION
1.1 General Background of Problem
Sports injuries, natural disasters, and conflicts resulting from the global war on terror have
all contributed to the increase in unmet demand for maxillofacial and craniofacial bone repair
materials. Surgeons have an arsenal of repair strategies for the uniquely shaped functional bones
involved in such injuries, but these are usually inadequate and often invasive, causing pain and
prolonging healing time [1]. Typically, autologous bone grafts (autografts), taken from another
site on the patient, are seen as the “gold standard” of bone repair; of course this technique is nonideal, since it requires multiple surgical sites and morbidity at the donor site [2]. The next standard
graft material, allogenic bone grafts (allografts), taken from another patient, carry risk of disease
transmission [2]. The unmet demand for high quality bone grafts to replace the gold standard
autologous bone grafts has fueled substantial research in the area of bone tissue engineering.
Researchers in the field of tissue engineering and regenerative medicine continue to
develop promising new strategies aimed at building bone grafts from readily available materials,
negating the need for autografts or allografts. In general, the tissue engineering strategy involves
fabricating a porous scaffold (usually composed of metal, ceramics, polymers, or some mix of
these materials), and seeding them with autologous cells that will (ideally) infiltrate the scaffold
via the pores, and secrete a mineralized matrix that will be further developed into bone [3]. Bone
marrow mesenchymal stem cells (MSCs) are a standard cell source for bone tissue engineering,
since they are readily available via isolation from the iliac crest of the patient with the bone injury
[4]. Moreover, researchers and physicians can induce MSCs to differentiate to osteoblasts (a
process termed osteogenesis), cells that secrete a mineralizing, bone like extracellular matrix
(ECM).
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Despite the promises of tissue engineering for bone regeneration, the current results still
show significant limitations, specifically with regard to limiting the invasive procedures associated
with maxillofacial and craniofacial bone repair. Moreover, researchers and physicians currently
have difficulty designing tissue engineering strategies that facilitate the rapid formation of a blood
vessel network within tissue engineered bone implants; because a vascular system is required for
large-scale bone regeneration, the inability to quickly regenerate a blood vessel network
throughout the implant is significantly inhibiting the field of bone regeneration [5, 6]. A deviation
from traditional tissue engineering techniques could facilitate the development of a bone
regeneration solution that enables the rapid development of a vascular system simultaneously with
the regeneration of bone matrix deposited by differentiating MSCs.
1.2 Modular Tissue Engineering
The emerging field of modular tissue engineering focuses on fabricating whole macroscale tissues from micro-scale constructs. Typically, the micro-scale constructs are modular units
containing cells surrounded by a biomimetic microenvironment, or simply cell aggregates or sheets
without any foreign material introduced. Fig 1 contrasts the modular approach with the traditional
tissue engineering approach [7]. Traditional tissue engineering often employs a “top-down”
approach, in that cells are seeded onto a porous scaffold (made of biocompatible and biodegradable
material), where they are expected to migrate throughout the pores of the scaffold (from the top,
down), secreting matrix, and proliferating to the extent that they replace the volume of the
degrading scaffold material. The traditional top-down approach has significant limitations,
including diffusion of nutrients and growth factors through the bulk of the scaffold, resulting in
engineered tissue limited to 100-200 microns thick [8]. Moreover, cells seeded onto traditional
porous scaffolds typically don’t migrate to significant depths through the scaffold, resulting in
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non-uniform distribution of cells. Similarly, such scaffold seeding techniques cannot facilitate
controlled distributions of multiple types of cells, and thus cannot mimic the complexity of desired
tissues, such as a network of blood vessels.
The modular approach to tissue engineering builds the larger macro-scale tissue from
smaller modular units in a bottom-up strategy. The modular units impart a great deal of freedom
in recreating the unique biomimetic features at the micro-scale level, that can recreate the
architecture of complex tissues. Multiple strategies exist to fabricate the modular units, including
self-assembled aggregation of the cells used [9], micro-fabrication of hydrogels containing cells
[10], layer-by-layer stacking of cell sheets [11], or by direct cell printing [12]. After fabrication,
the modular units can then be assembled into macro-scale tissues by randomly assembling the
units, stacking the layers, or by directed assembly of the modular units.
The modular approach to tissue engineering alleviates many of the limitations of traditional
tissue engineering. Fabricating the modular units with a uniform number of cells guarantees
uniform cell distribution upon assembly of macro-scale tissue. Constructing macro-scale tissues
from modular units that contain different cell types facilitates organization of complex engineered
tissues: for example, a modular tissue engineering approach that combines endothelial, smooth
muscle, and fibroblast cell sheets to recreate the three cell layers of a blood vessel [11]. Finally,
assembling the modular units in a controlled fashion can design the desired porosity into the
macro-scale tissue, from the bottom up, facilitating nutrient and waste diffusion into and out of the
engineered macro-scale tissue. Sufficiently small modular units can be used to create the basis of
a “bio-ink” for a 3D printing strategy to regenerate tissue of varying architecture, or as the basis
of an injectable bone regeneration therapy, where the modular units
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are injected to the defect site and fuse in situ.
1.3 General Approach to the Problem
The series of studies proposed here seeks to design a new bone regeneration platform,

Fig 1.1: Bottom-up (modular) and top-down (traditional) approaches to tissue engineering. In the bottom-up
approach, there are multiple methods for creating modular units, which are then assembled into engineered tissues
with specific microarchitectural features. In the top-down approach, cells and biomaterial scaffolds are combined
and cultured until the cells fill the support structure to create an engineered tissue [7]

involving the construction of larger, porous bone tissue constructs from small modular units, using
either a 3D printing strategy or direct injection to a site of bone loss. The modular units will be
formed from the encapsulation of MSCs and endothelial cell progenitors (EPs, effectively derived
from MSCs differentiated to an endothelial cell lineage) with a bone-like ceramic (hydroxyapatite,
HAP) in a polyelectrolyte membrane. The encapsulated MSCs will serve as an osteoprogenitor
cell population, capable of differentiating into bone ECM depositing osteoblasts, and the EPs will
aid in the rapid establishment of a blood vessel network throughout the larger bone tissue construct.
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Because the bone tissue construct would be entirely constructed of cell-laden micromodular units,
traditional cell seeding of the construct is unnecessary. Furthermore, the inclusion of EPs
throughout the tissue construct, coupled with its porosity, should enable the rapid establishment of
a blood vessel network throughout the construct, further aiding the bone regenerative properties of
the platform.
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CHAPTER 2: RELEVANT BACKGROUND
2.1 Current Gold Standard of Bone Tissue Engineering:
Mastication and ingestion are both critical for survival, as both are the first steps in nutrient
absorption from food in healthy and able individuals. Unfortunately, patients suffering from bone
defects due to trauma, tumor removal or abnormal skeletal developments concurrently suffer from
decrease in masticatory power when the trauma occurs to the maxillofacial bone [13]. Prosthetic
jaws and dentures only superficially restore masticatory ability, as mastication in patients fitted
with these devices is still reduced to 20% of patients with natural dentition [14]. Thus, bone tissue
regeneration (rather than superficial replacement), represents an important challenge for oralmaxillofacial and plastic surgeons tasked with restoring function to the unique bones of the face
and jaw. Autologous bone grafts taken from an uninjured area of the patient’s skeleton, are
frequently used for bone reconstruction, and this material is prized as the “gold standard” of bone
repair. Use of the patients own bone is desirable because it lacks immunogenicity, contains a blood
vessel network, and directly provides bone forming cells to the injured site; however, the process
of removing bone from a patient causes obvious morbidity at the donor site, post-operative pain,
increased risk of infection, and hypersensitivity to mechanical stress at the affected area [1, 2, 4].
Surgeons have looked to allogenic bone from human cadavers to avoid the problems associated
with autologous grafts. However, the immunogenic potential of allogeneic bone grafts and the risk
of virus transfer from donor to recipient represent a serious disadvantage [3]. Furthermore,
allogeneic bone has decreased vascularization and a higher resorption rate compared to autologous
bone, resulting in a lower rate of bone tissue formation in vivo [15]. Surgeons require new bone
graft materials to adequately repair and replace bone in patients with serious bone loss.
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2.2: Bone hierarchal structure and matrix materials
Like all other tissues, bone is composed of multiple types of biological compounds and
cells, with a hierarchical organization spanning several orders of magnitude from the macro-scale
(centimeter) to the nano-scale (individual material-material interactions). Specifically, bone ECM
is composed of both a non-mineral organic component (collagen type-1 and non-collagenous
proteins) and a mineralized inorganic component (carbonated apatite mineralites, predominantly
hydroxyapatite, HAP) [16]. In fact, bone ECM consists largely of an architecture of collagen fibers
plated with HAP nanocrystals, essentially making the tissue a ceramic/polymer composite: this
composite architecture imparts the toughness and compression resistant mechanical properties
characteristic of bone. Moreover, bone has anisotropic porosity and mechanical properties. The
outer “shell” of bones are made of highly compact mineralized tissue termed “cortical” bone,
which has a porosity of 5-10%, a compressive strength of 100-230 MPa and an elastic modulus of
12-20 GPa: by contrast, the center of a piece of bone tissue (termed cancellous bone) will have
increased porosity (20-30%), decreased compressive strength of 2-12 MPa, and a decreased elastic
modulus of 0.2-0.8 GPa [17]. Cortical bone is composed of osteons, roughly cylindrical structures
about 200 μm in diameter surrounding a blood vessel [17]. Unlike a simple bulk ceramic/polymer
composite, the changing mineralization and porosity throughout bone imparts complex mechanical
properties to the tissue. A multitude of non-collagenous proteins, including osteocalcin [18],
osteopontin [19], osteonectin [20], are responsible for calcium sequestration, attachment and
migration of bone remodeling cells, and attachment of HAP to collagen, respectively, imparting a
wealth of physiological signals throughout the tissue. Bone contains a relatively small amount of
glycosaminoglycans (GAGs), of which chondroitin 4-sulfate (C4S) predominates [21]. Research
has demonstrated that C4S promotes osteoblast differentiation during bone healing (possible via
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the binding of growth factors), and supported bone mineralization via calcium ion sequestration
[22]. Bone is organized into a hierarchical structure from the micro-level of ECM composition to
the macro-level spatial distribution of the tissue components (porous vs. cortical bone, etc…), and
each level contributes to the overall mechanical properties and function of bone.

Fig 2.1: Hierarchal organization of bone. Schematic depicting a cutaway cross-section of long bone, showing
the osteons encircling the network of blood vessels in the cortical (compact) bone, and weaving through the porous
cancellous (spongy) bone towards the center of the long bone shaft. The cutaway section above shows the lacuna
of the osteon with embedded osteocytes. Figure from [23]

The hierarchal organization of the materials that comprise bone extends to the cell types
that inhabit the bone microenvironment as well. Calcified bone is metabolically active, and
osteocytes are found embedded within the calcified bone ECM. Osteocytes are derived from boneforming cells called osteoblasts, which is the main cell type responsible for depositing a calcified
ECM: while osteoblasts mainly deposit the calcified ECM, osteocytes are responsible for secreting
various bone specific proteins (BSPs) (osteocalcin, osteopontin, osteonectin, etc…) that facilitate
cell attachment, ECM calcification, and remodeling of bone ECM [24]. Osteoblasts migrate to the
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bone surface, begin depositing their ECM and, as they surround themselves with their deposited
matrix, they effectively burry themselves: the buried osteoblasts then begin to differentiate to
mature osteocytes [25]. Both osteoblasts and osteoclasts are derived from mesenchymal stem cells
(MSCs), typically originating from the bone marrow cavities of cancellous bone. Bone is in a
constant state of remodeling, and thus a bone ECM resorption/metabolizing process compliments
the bone ECM forming/depositing process. Specifically, osteoclasts dissolve bone via acidification
and proteolysis of the collagen fibers comprising the bone matrix, which facilitates detachment of
HAP crystals once linked to collagen [26]. The process of bone resorption removes old structurally
unsound bone, injured bone, and controls the shape of bone during development, thus
complimenting the process of bone formation. The division of remodeling processes in specific
bone cell types represents another level of cellular organization of the tissue.
When moving from the outer cortical regions of bone towards the inner cancellous regions,
the cell population of bone changes to have a higher density of MSCs. MSCs reside in the bone
marrow in the inner cancellous regions, and are classified by their ability for 1) self-renewal and
2) differentiation to multiple mature cell lineages; as mentioned above, these cells differentiate
into osteoblasts [27]. During development in mammals, bones form by the differentiation of MSCs
to an osteoblastic precursor cell, and subsequent mobilization to the surface of the bone, where the
precursor cell finishes differentiation to an osteoblast [28, 29]. Once the MSCs have differentiated
to the osteoblast phenotype, they display several of the osteoblast characteristics, such as calcium
deposition and enhanced alkaline phosphatase (ALP) enzyme activity; in fact, the osteoblast
characteristics are used by researchers to denote early MSC differentiation (by increase and peak
in ALP activity) and late MSC differentiation (deposition of bone specific proteins) [30, 31].

10

Researchers and clinicians can make use of the inherent osteogenic ability of MSCs in designing
therapies to replace damaged tissue, specifically bone.
2.3 Vascularization of bone and bone healing:
Apart from being complex at the matrix and cellular level, bone is also highly vascularized.
Studies of blood vessels in long bones (femurs and tibia) indicate that the vessels form an organized
network throughout the bone marrow, cortical and periosteal region of bone, with vessels varying
in dimension between 10 – 200 μm [32]. Studies of human bone show that the osteons, containing
the blood vessels in cortical bone, are distributed homogenously [33]. In fact, studies of human
bone show that osteocytes are never more than 100 μm distance from a capillary, and this is
possibly a necessity, due to the metabolic requirement of osteoblasts and MSCs [34]. The vessels
in bone are lined primarily with endothelial cells (ECs), which constitute the fourth major cell type
found in bone. ECs in the microvasculature form tube-like conduits, sealed by adherin junction
proteins between opposing endothelial cells, to create a network of capillaries from patches of
endothelial cells sealed by cell-cell contact proteins. Specifically, platelet endothelial cell adhesion
molecule 1 (PECAM-1) aids in junction formation between ECs, and EC anchorage to the ECM,
and PECAM-1 is considered an endothelial marker.
Blood vessel networks require more than ECs to reach a non-permeable state with low ECcell migration and turnover (i.e., form stable blood vessels). In mature blood vessels, the EC
conduit is actually re-inforced and stabilized by cells called pericytes, which wrap around the
vessel and generally inhibit vessel permeability (generally, because certain growth factors like
VEGF or pathologies can interrupt pericyte stability) [35]. Pericytes maintain blood vessel
structural integrity by the contractile protein α-smooth muscle actin (α-SMA), which prevents
vascular permeability by contracting around ECs [35]. Some evidence shows that MSCs serve as
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a cell source for pericytes [36]. Studies suggest that pericytes send direct or paracrine signals that
induce endothelial differentiation and growth arrest, further stabilizing vessel formation [37]. A
schematic cross-sectional view of a mature blood vessel, enveloped by pericytes, is shown in fig.
2.3 and gives another example of the scale of organization found in blood vessels. Vascularization
plays a significant role in almost all tissue regeneration and healing, and bone is no exception.
Large bone defects typically heal via callus production in four overlapping phases, shown in fig.
2.2a [38]. Following damage to the musculoskeletal system and blood vessel network, the
coagulation cascade activates and forms a hematoma, enclosing the fracture area [39]. The
hematoma formation is associated with the release of several growth factors and cytokines that
initiate cell migration to the defect, including stem cells and endothelial cells [39]. Eventually,
blood vessels grow into the hematoma, and the hematoma is replaced by an immature vascular
network surrounded by fibrocartilage (internal callus) and mineral deposited by intramembranous
ossification (external callus), involving the differentiation of a chondrocyte precursor to an
osteoblast lineage which initiates calcified matrix deposition [40]. Further osteogenesis of the stem
cells and deposition of their calcified ECM transforms the callus from woven bone, which is finally
remodeled into secondary lamellar bone. Fig. 2.2b demonstrates overlapping phases in the microcomputed tomography (μCT) images of a rat femur healing from fracture [41]. The recruitment of
ECs so early in the bone healing process demonstrates how crucial vascularization is to bone
regeneration; thus, the inability to properly regenerate bone quickly in many bone tissue
engineering solutions may stem from an inability to recapitulate the blood vessel network required
in the earliest part of bone regeneration.
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Fig 2.2: Role of vascularization in bone healing: Hematoma formation. Image series (A) shows the stages of
fracture repair, including (a) hematoma formation after blood vessel disruption from injury; (b) soft callus formation
and the invasion of new blood vessels within the hematoma; (c) hard callus formation as osteoblasts begin secreting
a mineralized matrix; (d) bone remodeling, in which the large fracture callus is replaced with physiological bone
ECM. Figure from[38]. Image (B) below shows the phases of bone healing in a rat femur at 3, 6 and 12 weeks post
fracture. Figure from [39]
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Fig 2.3: Cross-section of a capillary. The schematic to the left shows the layout of a capillary, where an endothelial
cell conduit is stabilized by pericytes and vascular smooth muscle cells (PC/vSMC). Fluorescent image to the right
shows a histological cross-section of a capillary, with fluorescent probes for lectin (marker for endothelial cells,
green), αSMA (red, pericytes) and the nucleus of both cell types (DAPI, blue) [35].

2.4 Traditional tissue engineering bone regeneration materials:
Much of the research until the last few years has focused mainly on combining osteoblast
progenitors (OS-progenitors) such as MSCs, with materials that mimic the bone
microenvironment, such as various ceramic and hydrogel formulations. HAP, due to its chemical
similarity to bone, has been used extensively in tissue engineered scaffold generation: an example
study involved the use of a cylindrical collagen-HAP polymer/ceramic composite, seeded with
OS-progenitor cells, to regenerate bone in a mouse critically sized calvarial defect [42]. The
collagen-HAP scaffold seeded with OS-progenitors did exhibit significant bone regeneration in
vivo; however, the defect, and thus scaffold, was only 500μm thick, and did not adequately
recapitulate the nutrient diffusion limitations that would be experienced in larger bone defects
found in human patients. Villa et al commented in their study that the small size of the scaffold
(3.5 mm diameter x 0.5 mm height) likely wouldn’t be subjected to diffusion limitations, and that
a vascularization strategy would be required to regenerate larger bone defects [42]. Still, the study
validated the efficacy of HAP as a biomaterial for bone regeneration.
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Other groups have demonstrated the utility of biological and non-cytotoxic polymers to
regenerate bone. GAGs are an obvious choice, due to their non-cytotoxicity and ability to sequester
and attenuate growth factors [43, 44]. Because C4S is the major GAG constituent of bone ECM,
many researchers have used this as their main material for bone regeneration, and previous studies
have shown that C4S promoted osteoblast differentiation and supported bone mineralization
during bone healing [22, 45]. Chitosan is a carbohydrate derived from deacetylated chitin
(typically obtained from marine animals) and composed of β-(1→4)-2-acetamido-d-glucose and
β-(1→4)-2-amino-d-glucose unit linkages [46]. Chitosan has also been investigated for its utility
as a bone tissue engineering scaffold material, due to its ease of scaffolds preparation, relative noncytotoxicity, and the ability of its positive charge in acidic solution to sequester calcium ions [46].
Chitosan is biodegradable in vivo and can be complexed with negatively charged polymers such
as GAGs, making it a useful base material to design a bone regeneration system [47].
2.5 Current research towards generating vascularized bone:
With the understanding that establishing a vascular system is critical for bone regeneration,
many research groups have attempted to recapitulate the vascular system by seeding traditional TE
scaffolds with a combination of osteoprogenitors (usually MSCs) and endothelial progenitors
(usually HUVECs). Research elucidated that ECs can have stimulatory effects on MSC
osteogenesis when cultured in 3-dimensions. Kang et al cultured HUVECs and MSCs on porous,
cylindrical β-TCP scaffolds (5mmx7mm) in vitro, found that the HUVECs significantly increased
the ALP activity, and the effect was greatest for HUVECs seeded at a ratio of 1:1 HUVECs:MSCs
[48]. Furthermore, the HUVECs in the HUVEC:MSC cultured expressed the cell adhesion
molecule PECAM-1, which is known to be crucial for vessel formation and maintenance, and the
HUVECs formed a branched, networked architecture within the implant. In a similar experiment,
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Pedersen

et

al

seeded

6mm

diameter

cylindrical

poly(l-lactide)-co-(1,5-dioxepan-2-

one)[poly(LLA-co-DXO)] scaffolds with HUVECs and MSCs in a 1:5 ratio HUVEC:MSC, and
investigated the osteogenic and angiogenic potential of this system in a NOD mouse subcutaneous
skin pouch model [49]. Histological evaluation of the subcutaneous-implant scaffolds
demonstrated that α-SMA (a marker for pericytes) was found surrounding functional blood vessels
(marked by the presence of red blood cells) of both MSC and HUVEC:MSC co-cultures, with no
difference between the groups. Interestingly, ALP gene expression was highest for HUVEC:MSC
seeded scaffolds compared to MSC alone, and is likely due to signaling between HUVECs and
MSCs. The co-culture of ECs with MSCs clearly enhances MSC osteogenesis, while still
permitting EC cell function.
The co-culture of endothelial cells with MSCs has proven to enhance the overall
architecture of newly deposited bone ECM by differentiating MSCs. In one study, Yu et al
fabricated poly-ε-caprolactone (PCL) HAP composite scaffolds, seeded with both MSCs and ECprogenitors (derived from MSCs differentiated to an endothelial lineage), and investigated the in
vivo regeneration of vascularized bone in a rat femur model [50]. After 6 weeks, the PCL/ECprogenitor/MSC implant contained a significantly higher capillary density (compared to MSC only
control) demonstrated by an increase in concentric positive CD31 and Flt-1 staining. Interestingly,
because Yu et al used a sex-mismatched model (male-donor cells were implanted in female rats),
the donor cells in the implants could be tracked by staining for the presence of Y-chromosomes;
results showed that the new blood vessels were primarily composed of Y-chromosome+ donor
cells via Y-chromosome and CD31+ overlap, indicating that the addition of exogenous ECprogenitors enhanced vascularization of the scaffold (see fig. 2.4). The results from the study by
Yu et al demonstrate that not only do the EC-progenitors and MSCs enhance vascularization and
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osteogenesis within a HAP-based scaffold, but these implanted cells contribute significantly to the
formation of the vessel network. The enhanced vascularization from the EC-progenitors seeded in
the PCL/HAP scaffolds investigated by Yu et al also significantly enhanced the mechanical
properties of the implants: after 6 weeks of implantation, mechanical compression of implants
demonstrated that implants containing EC-progenitors had significantly higher ultimate tensile
stresses (0.728 + 0.092 MPa) compared to implants with OS-progenitor MSCs only (0.450+ 0.066
MPa). The inclusion of EC-progenitors in other bone regeneration systems should lead to enhanced
bone regeneration over OS-progenitors alone.

Fig 2.4: Donor cell contribution to vascularization and osteogenesis in a tissue engineered bone graft. Tissue
sections from a PCL/HAP implant seeded with EC-progenitors and MSCs and implanted in rat femur defect for 6
weeks. Sections were stained for presence of Y-chromosome (red dots) and CD31 (green) in image (a) to identify
EC-progenitors, and osteocalcin (green) in image (b). The nucleus of all cells was stained by DAPI (blue). Images
show that the donor cells, containing the Y-chromosome (red arrows aid in identification), contribute significantly
to both vascularization and bone specific protein deposition [50].

2.7 Technology gap in the literature:
Tissue engineering research has accomplished several key milestones in the effort to
produce functional TE bone grafts that can completely replace the gold-standard and morbidity-
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causing auto-graft bone. Currently, the literature has validated the use of ceramic and polymer
materials (HAP and various natural polymers), and OS-progenitors and EPs. However, the bone
TE literature currently lacks studies evaluating the design of a bone regeneration strategy
composed of small modular units, simultaneously laden with OS-progenitors and EPs and
compression-resistant ceramics, to regenerate highly vascularized bone: the evaluation of a
platform incorporating such a strategy is the goal of this study.
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CHAPTER 3: CENTRAL HYPOTHESIS and SPECIFIC AIMS
Our modular bone regeneration platform employs polysaccharide microcapsules
containing encapsulated MSCs and HAP microgranules. The polysaccharide microcapsule
membrane is composed of a C4S/chitosan polyelectrolyte complex, is relatively thin and porous,
and facilitates the diffusion of nutrients and growth factors to support encapsulated cell viability
and differentiation. The microcapsules can be fabricated at an average diameter of 400 μm. The
microcapsule materials are biodegradable in vivo, and the degradation rate depends on materials.
These microcapsules will serve as the basis of our modular bone regeneration platform.
The central hypothesis to be tested is that modular GAG/HAP/Chitosan microcapsule
constructs can support osteogenesis of encapsulated MSCs, mineralization to a compression
resistant tissue, and rapidly vascularize in vivo when coated with endothelial progenitors. This new
bone graft design will serve as the basis of a bone regeneration platform that, with subsequent
optimization, will regenerate bone in defects from injury or disease (fig 3.1).
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Fig 3.1: Central hypothesis. Microcapsules containing encapsulated osteoprogenitors and HAP ceramic
microgranules, with endothelial progenitors attached to the exterior, can be fused into implantable constructs that
will quickly regenerate vascularized bone in vivo.

The specific aims of this project are to:
1. Examine the ability of C4S/HAP/Chitosan microcapsules to support osteogenesis of
encapsulated MSCs.
2. Characterize how microcapsule mineralization influences mechanical properties of fused
microcapsule constructs.
3. Analyze how endothelial progenitors attached to the microcapsule exterior influence the
vascularization of fused constructs in vivo.
3.1 Overall research design
First, the ability of the microcapsule materials to support proliferation, viability and
osteogenesis of encapsulated mesenchymal stem cells (MSCs) was assessed. Secondly, the
mechanical properties of fused constructs composed of microcapsules actively mineralized by
MSCs were characterized. Additionally, the influence of mineral architecture on mechanical
properties was investigated. Finally, the ability of EPs attached externally to microcapsules to
enhance the vascularization of fused constructs in vivo was evaluated.
3.2 Significance and rationale
Modular tissue engineering principles have great potential to help engineer advanced
tissues by facilitating greater control over multicellular organization, unique material composites,
and deployment of scaffolds via minimally invasive surgery. The field of modular tissue
engineering is relatively new, and will certainly benefit from a new cell/material combination
strategy. This study is very significant: many modular tissue engineering studies understandably
focus more on mimicking the multicellular organization of native tissues, and not necessarily the
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mechanical properties. This study has the capability to not only reproduce tissue with a level of
cell organization (endothelial and MSC/osteoprogenitor) similar to bone tissue, but the inclusion
of ceramic particles in the microcapsules allow us to produce tissue with enhanced mechanical
properties as well.
The modular system described here is versatile, and can accommodate various
osteoprogenitor and endothelial progenitor cell types, bone-like mineral, and polymer additives to
the microcapsule membrane. Thus, this study holds the promise to produce a new bone graft design
that could generate well vascularized bone with some early mechanical stability in vivo, in a system
amenable to minimally invasive surgical delivery. This new bone regeneration platform could take
the place of the current gold standard of bone regeneration (autologous graft harvesting), since this
modular design requires only autologous stem cells (harvested in a much less invasive procedure),
or allogenic stem cells from a tissue bank. Moreover, the design of a modular construct with
organization of multiple cell types could provide a blueprint for other tissue engineers seeking to
regenerate complex organs with high degrees of material and cell organization (kidney nephrons,
liver lobules, etc…). The microcapsules used for this modular bone regeneration platform could
provide tissue engineers with another tool to fabricate advanced tissues.
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CHAPTER 4: EVALUATION OF OSTEOGENIC DIFFERENTIATION OF
MESENCHYMAL STEM CELLS ENCAPSULATED IN
MICROCAPSULES
4.1 Introduction:
GAG/Chitosan/HAP microcapsules must support encapsulated MSC osteogenesis and
viability if the microcapsules are to form the basis of any bone regeneration platform. These criteria
are a minimum for any bone regeneration strategy that uses stem cells as the primary tissue
regeneration component. In this chapter, encapsulated MSCs were induced to osteogenesis while
in microcapsule culture, and the extent of osteogenesis was characterized via quantification of
osteogenic biomarkers and cell-deposited bone-like matrix components. Additionally, cell
viability was assessed over the four weeks of static microcapsule culture. Furthermore, the effects
of HAP microgranules on encapsulated MSC osteogenesis were also explored.
4.2 Aim and Rationale:
The main specific aim of this chapter is to examine the ability of the GAG/Chitosan/HAP
microcapsules to support encapsulated MSC osteogenesis and viability. The rationale for this aim,
is that by examining the osteogenesis of encapsulated MSCs in vitro, we can confirm that the
microcapsule materials will not inhibit MSC bone regeneration in vivo. This aim is significant,
because it will allow us to determine if the present microcapsule system is sufficient for the basis
of a bone regeneration platform, or if the microcapsule materials/organization requires
modification. Moreover, mineralization of the microcapsule system could enhance the mechanical
properties of a tissue construct composed of fused microcapsules. Confirming that the
microcapsule system supports MSC osteogenesis and mineralization will allows us to analyze
fused construct mechanical properties as a function of mineralization, and continue modifying the
microcapsule system to promote vascularization.
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4.3 Experimental Approach:
Study 1: Viability of MSCs encapsulated in GAG/Chitosan/HAP microcapsules
Encapsulated MSCs were cultured for four weeks in static conditions, and the effects of
osteoinduction and HAP microgranules on MSC viability were assessed. Double stranded DNA
(dsDNA) was quantified at each week of culture to quantify cell proliferation.
Study 2: Quantification of Osteogenic Biomarkers of Encapsulated MSCs
Common osteogenic biomarkers for MSC osteogenesis were quantified to determine whether
microcapsule materials or culture could inhibit osteogenesis. ALP activity (early stage
osteogenesis), osteocalcin secretion (early stage osteogenesis) and osteopontin secretion (late stage
osteogenesis) were quantified for the four-week culture period. This allowed us to confirm that
encapsulated MSCs were differentiating along an osteogenic path.
Study 3: Characterization of Cell-deposited ECM in Microcapsule Interior.
Cell-deposited matrix in the microcapsule interior was observed after four weeks of culture. The
amount of collagen and deposited calcium was quantified over the four-week culture period. This
study allowed us to confirm that differentiating cells were depositing bone-like mineral in the
microcapsule system.
4.4 Materials and Methods:
Unless otherwise noted, all chemical and cell-culture reagents were purchased from SigmaAldrich (St. Louis, MO), and were of reagent grade or greater purity. Fetal Bovine Serum (FBS)
was purchased from Atlanta Biologicals (Flowery Branch, GA).
4.4.1 Cell culture conditions
MSCs were harvested from the femurs and tibiae of Sprague-Dawley (SD) rats (Envigo,
Huntingdon, UK), using an established protocol [51]. Briefly, the femur and tibiae of SD rats were

23

removed and cleaned of excess soft tissue post-euthanasia, and incubated in a Kreb’s-Ringer buffer
solution containing antibiotic (gentamicin sulfate, 50 mg/L) and antifungal (2.5 mg/L amphotericin
B). After an hour of incubation at 4 ºC, the diaphyses of the bones were removed, and the contents
of the bone marrow were flushed out with Low Glucose Dulbecco’s Modified Eagle’s Medium
(L. DMEM) at 37 ºC, filtered through a 70 μm cell strainer, and centrifuged at 200xg for 6 minutes.
After removing supernatant, the resulting cell/erythrocyte pellet was resuspended in PBS, and
centrifuged again to wash away erythrocytes. After repeating the washing step twice, the MSCs
were suspended in standard medium (L. DMEM + 10% FBS) and seeded at a density of 10,000
cells/cm2 in tissue culture plates. MSCs were maintained in 2D culture for expansion in standard
medium at 37 ºC in a humidified 5% CO2 atmosphere. MSC were cultured until 80% confluency
and subsequently subcultured, or used for an encapsulation at passage 4.
4.4.2 Microcapsule Fabrication
C4S/Chitosan/HAP microcapsules were prepared following an established protocol, with
slight modifications to encapsulate MSCs and HAP granules [52]. A schematic of the microcapsule
formation is shown below (fig. 4.1). MSCs and HAP microgranules were suspended in a C4S
solution (4% w/v C4S and 1.5% CMC in Sorbitol-HEPES ((4-(2-hydroxyethyl)-1piperazineethanesulfonic acid)) buffer, pH 7.0), at a density of 5x106 cells/ml C4S solution, and
50% volume microgranules/volume C4S solution. The Sorbitol-HEPES buffer contained the
following components: 0.4 g/l KCl, 0.5 g/l NaCl, 3.0 g/l HEPES*Na, and 36 g/l Sorbitol, adjusted
to pH 7.4 with 1.0 M NaOH. The resulting C4S solution with suspended MSCs and microgranules
was extruded through a 24-gauge catheter as 400 μm droplets, into a rapidly stirring solution of
0.6% (w/v) high molecular weight chitosan and sorbitol. Once the C4S/HAP/MSC suspension hits
the chitosan, the C4S complexes with the chitosan, encapsulating the contents of the droplet (HAP
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and MSCs). The microcapsules are washed with 0.9% saline 3x, and the positive outer shell of the
microcapsules is surface stabilized by washing with a 0.1% (w/v) polygalacturonic (PGA) acid
solution. After another saline wash to remove unreacted PGA, the resulting microcapsules
(containing the MSCs and HAP microgranules) were equilibrated with cell culture medium,
transferred to a dish, and incubated at 37 °C in a humidified 5% CO2 atmosphere. Two
microcapsule conditions (with HAP microgranules and without) and two medium conditions
(osteogenic and expansion) were used to elucidate the effects of HAP microgranules and
osteogenic or expansion media on MSC osteogenesis and viability. Thus, four microcapsule
conditions were generated: 1) encapsulated MSCs cultured in expansion medium (Exp), 2)
encapsulated MSCs cultured in osteoinduction medium (Osteo), 3) encapsulated MSCs and HAP
microgranules cultured in expansion medium (Exp + HAP), and 4) encapsulated MSCs and HAP
microgranules cultured in osteoinduction medium (Osteo + HAP). The medium employed
consisted of expansion medium (L. DMEM +10% FBS), and osteoinduction medium, consisting
of the expansion medium supplemented with 100 nM dexamethasone, 10 mM 𝛽glycerophosphate, and 50 𝜇M ascorbic acid-2-phosphate [53]. All media were supplemented with
9 μg/ml tetracycline to fluorescently visualize deposited calcium mineral.
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Fig 4.1 Microencapsulation of HAP microgranules and MSCs through complex coacervation. (a) Droplets of
MSCs and microgranules suspended in GAG solution are air extruded into rapidly stirring chitosan solution.
Interactions between polyanions in the GAG solution and the polycation chitosan form an insoluble polyelectrolyte
complex membrane that encapsulates MSCs and microgranules suspended in the droplets. Phase contrast image
showing microcapsules membrane and encapsulated HAP microgranules. Microscope objective is focused on
microgranules, so membrane appears out of focus.

4.4.3 Assessing Encapsulated MSC Viability
The approach employed involved culturing the four microcapsule conditions detailed
above for a series of four weeks, and investigating the viability of encapsulated MSCs using a
fluorescent probe. At 1, 2, 3 and 4 weeks of static culture, microcapsules were washed with
phosphate buffered saline (PBS), and incubated in L. DMEM supplemented with 4 μM Calcein
Red Orange (Calcein RO), at 37 °C in a humidified 5% CO2 for 30 minutes. After 30 minutes, the
microcapsules were washed with PBS twice to remove all extracellular Calcein RO, and the
cultures were examined under a fluorescence microscope for live cells containing fluorescent
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Calcein RO product. The tetracycline fluorescence of solid calcium deposited by differentiating
MSCs was also examined. All steps involving fluorescent probes were performed in the dark.
The dsDNA content of the microcapsules was quantified at each week using the
fluorescent, dsDNA binding Hoechst 33258 reagent [54]. After each week, a 0.2 ml volume of
settled microcapsules was removed from culture, washed with PBS, and combined with 500 μl of
cell lysis buffer (0.05% (v/v) Triton x-100 in 10 mM Tris Buffer, pH 7.0). The microcapsule/buffer
suspension was subjected to three freeze-thaw cycles via liquid nitrogen and microcapsules were
subsequently crushed with a mortar and pestle to release cell lysate. After cell lysis, 1.5 ml of a
Hoechst solution (100 ng/ml Hoechst 33258, 100 mM NaCl, 10 mM Ethylenediaminetetraacetic
acid (EDTA) dissolved in 10 mM pH 7.0 Tris buffer) was mixed with 50 μl of the cell/capsule
lysate solution, and incubated at room temperature. After 5 minutes of incubation, 200 μl of
Hoechst/cell lysate was transferred to a 96 well plate, where the fluorescence was recorded at an
excitation of 350 nm, and emission wavelength of 450 nm. Fluorescence data from microcapsule
samples was compared to a standard curve generated from calf thymus dsDNA.
4.4.4 Assessing Encapsulated MSC Osteogenesis
To examine the extent of early and late MSC differentiation to an osteogenic lineage, the
ALP activity and deposition of bone specific proteins (osteocalcin and osteopontin), respectively,
was quantified at timepoints of 1, 2, 3 and 4 weeks: all data was normalized to dsDNA content at
each timepoint. At each timepoint, microcapsules were removed from culture and washed with
PBS. The washed capsules were equilibrated with cell lysis solution (0.05% (v/v) Triton x-100 in
10 mM Tris Buffer, pH 7.0), and then cracked via shear with a mortar and pestle. A 0.2 ml volume
of settled microcapsules is sheared, and 1 ml of cell lysis buffer is added. The cell sheared
microcapsules are incubated in the lysis buffer for 15 minutes at room temperature. ALP activity
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was quantified using the conversion of p-nitrophenyl phosphate (p-npp) to a colorimetric product
by ALP activity. A spectrophotometer was used to quantify the colored product, which was
converted to a rate of nmol ALP activity divided by the dsDNA content. Briefly, 300 ul of cell
lysis buffer from sheared microcapsules was added to 1 ml of p-npp reagent (Pointe Scientific,
Canton, MI) pre-warmed to 37 ºC, and the mixture was incubated at 37 ºC for 30 min. The
absorbance of the lysate/p-npp mixture was quantified before (t0) and after (t30) the 30 min 37 ºC
incubation period: 300 ul of lysate/p-npp solution was aliquoted into a 96-well plate, and the
absorbance was read at 405 nm. The ALP activity was calculated using equation 1 below, and
standardized to the DNA content of the microcapsules. Results were reported as nM ALP/min/ug
dsDNA.
Equation 1: Calculation of ALP

nM
(𝐴30 − 𝐴0 )×1.2 ml
=
min 30 min× 18.75 nM −1 cm−1 ×0.7 cm ×0.300 ml

Activity from Absorbance
𝐴0 = Absorbance of cell lystate p − npp mixture at t = 0 min
𝐴30 = Absorbance of cell lysate p − npp mixture at t = 30 min

Osteocalcin and Osteopontin was quantified via a competitive ELISA similar to published
protocols [55]. ELISA plates (96-wells) were coated with either osteocalcin or osteopontin
(Abcam, Cambridge, UK) at 20 ng/well overnight at 4 ºC in 50 mM carbonate buffer (pH = 9.6).
Coated wells were washed 3x with TBS-T wash buffer (0.05 M Tris-HCl (pH 7.5), 0.15 M NaCl,
0.05% (v/v) Tween 20), and blocked for 24 hours at 4 ºC with 5% (w/v) non-fat dry milk (in TBST). Blocked wells were washed 4x with wash buffer. Microcapsule samples were prepared
similarly for OC/OP analysis as for ALP activity quantification: 125 μl of cell/capsule lysate (from
sheared microcapsules incubated with cell lysis solution) was added to a 125 μl primary antibody
(diluted 1:50,000 in blocking solution for both OC and OP), and the mixture was shaken for 24
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hours. The primary antibodies for OC and OP were rat anti-osteocalcin developed in mouse
(Thermo Fisher Scientific, Waltham, Massachusetts) and rat anti-osteopontin developed in rabbit
(Abcam, Cambridge, UK), respectively. After shaking, 250 μl of lysate/antibody solution was
added to the blocked wells of the 96-well plate, and incubated at 4 ºC for 24 hours. After 24 hours,
plates were washed 3x with wash buffer, and then 250 μl of alkaline phosphatase-conjugated
secondary antibody (1:2000 dilution in blocking buffer,) was added to the wells, and incubated for
24 hours at 4 ºC. The secondary antibodies used for OC and OP detection were anti-mouse IgM
alkaline phosphatase antibody produced in goat, and anti-rabbit IgG alkaline phosphatase antibody
produced in goat, respectively (Sigma Aldrich, St. Louise, MO). After incubation, the wells were
washed with wash buffer, and p-npp substrate (SIGMAFAST p-npp tablets, Sigma Aldrich, St.
Louis, MO) was applied to the wells. After 5 min, reactions were stopped with 1 M NaOH, and
the absorbance was read on a Spectramax 250 spectrophotometer (Molecular Devices, Sunnyvale,
CA) at 405 nm. A standard curve of OP and OC was used to determine the OC and OP content of
the microcapsule samples, and results were standardized to sample DNA content for reporting as
μg OC/μg dsDNA (or μg OP/μg dsDNA).
4.4.5 Characterizing Matrix Production in Microcapsule Interior
The amount of calcified matrix deposited by differentiating MSCs was quantified by the
orthocresolpthaliene-complexone (OCPC) indicator method established in the literature [56].
Briefly, the microcapsules fabricated above were removed from culture at 1, 2, 3 and 4 weeks, and
incubated in 1 M acetic acid for 24 hours. Every 24 hours, a 50 μl sample of the acetic acid/mineral
solution from the dissolving microcapsules was added to 250 μl of the OCPC detector solution,
and the absorbance of this solution was read on a spectrophotometer set to 570 nm. Data was
compared to calcium chloride standards, and microcapsules were incubated with fresh 1 M acetic
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acid until no calcium is detectable (3 days). Collagen content was quantified by measuring the
hydroxyproline (HYP) content of the microcapsules, using a published protocol [57]. Briefly,
extracts from the microcapsules were oxidized with chloramine T which, upon reaction with Pdimethyl-amino benzaldehyde, produces a colored product whose absorbance can be quantified
using a spectrophotometer set to 550 nm. Results were reported as ug calcium/ug dsDNA and ug
HYP/ug dsDNA.
4.4.6 Evaluating Matrix Interior Topography via SEM
The interiors of the microcapsules for all four conditions were assessed via Scanning
Electron Microscopy (SEM) after four weeks of culture, to characterize the cell-deposited ECM
and microarchitecture within the microcapsules. After four weeks of culture, microcapsules were
rinsed with PBS and fixed in 2.5% (v/v) glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for
24 hrs at 4 C. The fixed microcapsules were then washed twice with PBS to remove
glutaraldehyde, equilibrated with DI water for three changes, flash frozen with liquid nitrogen, and
lyophilized for 48 hours. After lyophilization, the microcapsules were fractured with a razor blade
to expose their cross-sections, and examined with SEM coupled with EDX spectrometry (JEOL
7600 FESEM, JEOL USA, Inc., Peabody, Massachusetts) for ECM microarchitecture, and the
relative distribution of calcium and phosphorus in the samples.
4.4.7 Analysis of Growth Rate of Encapsulated MSCs via alamarBlue®
The cell metabolism assessment reagent alamarBlue® (Invitrogen, Carlsbad, CA) was used
to assess cell metabolism and quantify cell proliferation, to determine whether mineral deposition
within microcapsules could limit cell proliferation by blocking nutrient diffusion. To accomplish
this, microcapsules for all conditions were immobilized to the bottom of 24 well plates, and
cultured on a rotary shaker. To immobilize the microcapsules, chitosan films were cast in the wells
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of the 24-well plate. A 1% (w/v) suspension of chitosan in DI H2O was sterilized by autoclaving,
and chitosan was subsequently dissolved with 0.2% acetic acid (added aseptically). Undissolved
particles were centrifuged out, and 200 μl of 1% chitosan solution were added each well of the 24wel plate, and air-dried (to allow acetic acid evaporation) under sterile conditions for 24 hours.
Microcapsules were prepared as previously described, and 0.1 ml of settled microcapsules were
added (in PBS at 37 ºC) to the films. The microcapsules attached to the films almost instantly, and
the PBS was aspirated, replaced with standard medium (L.DMEM + 10% FBS), and cultured on a
rotary shaker at 66 rpm with a 1 inch rotation diameter for 24 hours in standard culture conditions
(37 ºC and 5% CO2 hydrated atmosphere). After 24 hours, the culture medium was replaced with
either standard medium (Exp or Exp+HAP microcapsules) or osteogenic medium (Osteo or
Osteo+HAP) for 3 weeks. The metabolism of the encapsulated cells was quantified with
alamarBlue® 48 hours after the culture medium switch (week 0), and on 1, 2 and 3 weeks
afterward. A 10% (v/v) solution of alamarBlue/L.DMEM (without phenol red) was applied to the
immobilized cultures for 4 hours: after 4 hours, the resulting medium containing reduced
alamarBlue® was removed, 200 μl samples were aliquoted to wells of a 96-well plate, and the
fluorescence intensity was measured on a fluorimeter (Perkin Elmer, Waltham, MA) at an
excitation of 550 nm and emission of 590 nm. The percent reduction of alamarBlue® was
computed using equation 2 below:
Equation 2:
%Reduction
alamarBlue®

% Reduction =

𝐹𝐼𝑠𝑎𝑚𝑝𝑙𝑒 −𝐹𝐼𝑢𝑛𝑟𝑒𝑑𝑢𝑐𝑒𝑑
𝐹𝐼𝑟𝑒𝑑𝑢𝑐𝑒𝑑 −𝐹𝐼𝑢𝑛𝑟𝑒𝑑𝑢𝑐𝑒𝑑

×100%

𝐹𝐼𝑠𝑎𝑚𝑝𝑙𝑒 = Fluorescence intensity of alamarBlue/medium from microcapsules
𝐹𝐼𝑢𝑛𝑟𝑒𝑑𝑢𝑐𝑒𝑑 = Fluorescence intensity unreduced alamarBlue/medium
𝐹𝐼𝑟𝑒𝑑𝑢𝑐𝑒𝑑 = Fluorescence intensity of 100% reduced alamarBlue
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The specific growth rate of the encapsulated cells was calculated using the percent reduction of
alamarBlue® by equation 3, below:
Equation 3:
Specific Growth Rate of
Encapsulated Cells

𝜇=

𝑅
ln(𝑅 )
𝑜

(𝑡 − 𝑡𝑜 )

𝜇 = Specific growth rate (day-1)
𝑅 = Percent reduction alamarBlue at time t
𝑅𝑜 = Percent reduction alamarBlue at time to
𝑡𝑜 = Time 1 week previous to time t (days)

Results are reported as percent reduction of alamarBlue® and specific growth rate (Day-1) vs.
weeks of culture.
4.4.8 Statistical Analysis
Statistical analysis was carried out using GraphPad Prism software. All statistical
comparisons were made by performing a two-way analysis of variance (ANOVA), followed by
Bonferroni’s multiple comparison tests to evaluate significance between two data sets at a time
and correct for false positives of significance. P values less than 0.05 were considered statistically
significant. All data is reported as the mean + standard deviation.
4.5 Results:
4.5.1 Encapsulated Cell Viability and Mineral Deposition
MSCs were successfully encapsulated in C4S/chitosan complex microcapsules. MSCs
encapsulated in C4S/chitosan complex and cultured in standard media (Exp) formed aggregates
early at week 1 of culture (fig. 4.2a) that persisted through 4 weeks of culture (fig. 4.2b-d). MSCs
in Exp microcapsules typically formed one aggregate per capsule. Exp capsules maintained MSC
viability over all four weeks of culture, demonstrated by the presence of Calcein RO fluorescence
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localized to the cells, and not present over the entire field of view (fig. 4.2e-h). Encapsulated MSCs
in Exp capsules deposited very little calcified mineral, as evident by the absence of green
tetracycline fluorescence from weeks 1-3 of culture (fig. 4.2e-g); however, tetracycline
fluorescence was evident by week 4, indicating possible active MSC mineralization of capsule
membrane by week 4, since tetracycline is incorporated into newly-mineralized ECM (fig. 4.2h)
[58]. Moreover, the sections of the Exp microcapsule membrane appeared rough and thicker in
places by week 4 of culture, relative to prior weeks 1-3, indicating possible matrix deposition by
encapsulated MSCs (fig. 4.2d). The membranes of Exp microcapsules between weeks 1-3 had
appeared smooth.
MSCs encapsulated in C4S/chitosan microcapsules and cultured in osteogenic induction
media (Osteo) formed aggregates in the first week of culture (fig. 4.2i), but aggregates appeared
smaller than in Exp microcapsules, and capsules appeared to have multiple aggregates. Initially,
the Osteo microcapsule membrane was relatively homogenous and translucent. As osteoinduction
of the encapsulated MSCs continued, the microcapsule membrane exhibited a rougher appearance
and became increasingly opaque, due to mineral deposited by MSCs undergoing osteogenesis (fig.
4.2j-l). By week 2 of culture, Osteo microcapsules exhibited significant green tetracycline
fluorescence that increased to week 4, indicating that MSCs had deposited significant calcified
mineral in the microcapsules (fig. 4.2n-p). The tetracycline fluorescence in Osteo microcapsules
was localized around the capsule membrane and the MSC aggregates (yellow fluorescence was
due to green and red overlap). After four weeks of osteoinduction, the microcapsule membrane as
well as part of the capsule interior was intensely fluorescent with tetracycline and opaque,
indicating significant MSC-deposited calcified mineral (fig. 4.2l, p).
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Fig 4.2: Fluorescent images of capsules without HAP microgranules. (a-d) Phase contrast images of Exp
capsules in static cultures for weeks 1 – 4, (e-h) corresponding Calcein Red Orange (RO) and tetracycline
fluorescent images to (a-d). (i-l) Phase contrast images of Osteo capsules in static culture for weeks 1-4, and (m-p)
corresponding Calcein RO and tetracycline fluorescence. Significant calcium deposition was evident after 2 weeks
of osteogenesis, and localized around cells (yellow) and the capsule wall (green). (scale bars = 250 um)

Suspension of HAP microgranules in the GAG solution resulted in the coencapsulation of
HAP microgranules and MSCs. Gravity caused the HAP microgranules to settle towards one end
of the microcapsules. The addition of the completely opaque HAP microgranules made it difficult
to discern MSC position from the phase contrast microscope images alone, so observation of cell
position relied entirely on the Calcein RO fluorescence (fig. 4.3a-d, i-l). Calcein RO fluorescence
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around the microcapsule membrane demonstrates that including HAP microgranules and culture
in standard media initially disperses the cells to the membrane of the microcpasules in the
Exp+HAP condition at week 1 of culture (fig. 4.3e). The coencpasulation of HAP microgranules
maintained MSC viability over the four-week culture period, as demonstrated by fluorescence of
Calcein RO (fig. 4.3e-h). By week 2 of culture, the encapsulated MSCs had attached to the HAP
microgranules and formed an MSC/HAP microgranule composite aggregate inside the
microcapsules in the Exp+HAP condition that persisted through 4 weeks of culture (fig. 4.3f-h).
Very light tetracycline fluorescence was present after two weeks of culture in the Exp+HAP
condition, indicating active mineralization by encapsulated MSCs (fig. 4.3f). Acellular
microcapsules containing HAP microgranules did not exhibit tetracycline fluorescence (data not
shown).
HAP microgranules initially dispersed the MSCs in the Osteo+HAP condition, but by week
two, the MSCs had attached to HAP microgranules to form the MSC/HAP microgranule aggregate
(fig. 4.3m-p). MSCs in the Osteo+HAP microcapsules deposited mineral early during week one
of culture, as exhibited by tetracycline fluorescence (fig. 4.3m). MSCs continued to mineralize
Oste+HAP microcapsules through the four-week culture period: the tetracycline fluorescence (and
thus mineral deposition) was initially localized to the HAP microgranules, but later extended to
the microcapsule interior and possibly the microcapsule membrane (to a lesser extent).
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Fig 4.3: Fluorescent images of capsules with HAP microgranules. (a-d) Phase contrast images of Exp + HAP
capsules in static cultures for weeks 1 – 4, (e-h) corresponding Calcein Red Orange (RO) and tetracycline
fluorescent images to (a-d). (i-l) Phase contrast images of Osteo + HAP capsules in static culture for weeks 1-4,
and (m-p) corresponding Calcein RO and tetracycline fluorescence. (Scale bar = 250um)

4.5.2 Encapsulated Cell Proliferation
MSC proliferation in the microcapsule conditions was measured by comparing dsDNA
content in microcapsules at each week of culture. dsDNA content, and thus MSC proliferation,
showed a general upward trend for all microcapsule conditions through four weeks of culture (fig.
4.4). Microcapsules without HAP microgranules (Exp and Osteo) exhibited the fastest MSC
proliferation initially, between weeks one and two, while MSC proliferation in microcapsules with
HAP microgranules (Exp+HAP and Osteo+HAP) remained low. After week two, MSC
proliferation in Exp and Osteo microcapsules plateaued, and remained unchanged between weeks
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2 and 4 of culture. In contrast, MSC proliferation in Exp+HAP and Osteo+HAP microcpasules
increased between weeks 2 and 3 of culture, while remaining unchanged between weeks 3 and 4.
The lack of proliferation after week 2 in Exp cultures is likely due to the MSCs unable to fully
spread and adhere to the microcapsule interior wall (the cells attach as aggregates), limiting cell
proliferation by reducing focal adhesions. The cells in the Osteo microcapsules may be
experiencing low levels of nutrients due to mineralization of the microcapsule wall, that could
limit their proliferation. Because the HAP microgranules initially disperse the MSCs in the capsule
after encapsulation, the effects of cell-cell contact and growth inhibition are observed later after 3
weeks of culture.

Fig 4.4: Encapsulated MSC viability and proliferation in static culture. The total dsDNA of 0.2 cm3 samples
of capsules from each condition was quantified over all weeks of culture.
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4.5.3 Biochemical Markers of MSC Osteogenesis
Cell secreted ALP was quantified and normalized to dsDNA for all conditions over the
four-week culture period (fig. 4.5a). ALP significantly increased between weeks 1-3 for all
osteoinduced microcapsule conditions. The ALP activity for both osteoinduced conditions (Osteo,
Osteo+HAP) was significantly higher than the non-induced (Exp, Exp+HAP) at week 2, and
higher than Exp at weeks 3 and 4 (P < 0.05). The osteoinduced cultures hit a peak of ALP activity
after three weeks of osteoinduction before falling off by week 4. Interestingly, at week 3, MSCs
in Exp+HAP microcapsules had statistically similar ALP activity to the osteoinduced conditions
(P < 0.05).
Encapsulated MSCs deposited bone specific proteins in the microcapsules in response to
osteoinduction during microcapsule culture. Osteoinduced conditions (Osteo and Osteo+HAP)
contained significantly higher levels of secreted OP over weeks 3 and 4, compared to Exp and
Exp+HAP during the same time (P < 0.05, fig. 4.5b). Additionally, the osteoinduced conditions
exhibited an increasing microcapsule OP content between 1 and 4 weeks of culture. Microcapsule
OC content also increased in response to osteoinduction of encapsulated MSCs. MSCs cultured in
Osteo and Osteo+HAP microcapsules deposited significantly more OC than Exp microcapsules
between weeks 2-4 of culture (P < 0.05, fig. 4.5c). OC content of Osteo microcapsules was
significantly higher than Exp and Exp+HAP at week 2; however, by week 3, MSCs in Exp+HAP
had deposited a statistically similar amount of OC as Osteo (P < 0.05). Osteo, Osteo+HAP and
Exp+HAP microcapsules had significantly higher OC content than Exp microcapsules after 3 and
4 weeks of osteoinduction (P < 0.05). OC content in the Exp microcapsules increased between
weeks 2 and 3, but the amount was significantly lower compared to all other conditions (P < 0.05).
Osteoinduction of encapsulated MSCs was enough to stimulate expression of osteogenic markers
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ALP, OC and OP: additionally, HAP microgranules stimulated an upregulation of OC and ALP,
but not OP. The ability for HAP to stimulate osteogenesis in MSCs has been documented to a
limited extent, and previous studies have demonstrated co-culturing HAP and MSCs increased
ALP and BSP expressions, in the absence of other osteoinduction factors [59]. The osteoinduction
of MSCs cultured with HAP are likely due to calcium and phosphate ions released by HAP near
MSCs, that stimulate the upregulation of BMP-2 gene expression, leading to the expression of
osteogenic markers like ALP and BSPs [60].

Fig 4.5: Biochemical markers of MSC Osteogenesis. (a) Alkaline phosphatase (ALP) activity of MSCs in static
culture. (b) Osteopontin (OP) deposition by MSCs in static culture. (c) Osteocalcin (OC) deposition by MSCs in
static culture. *= P< 0.05 (N=4) relative to Exp. #=P < 0.05 (N=4) relative to Exp and Exp+HAP
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The increase in OC expression but not OP expression in Exp+HAP microcapsules was an
interesting finding for this series of experiments. Results from literature demonstrate that, in the
absence of other osteoinductive factors, inorganic phosphate at a 10 mM concentration in static
medium promotes OP expression via signaling through the extracellular signal-regulated kinase
(ERK1/2) pathway [61]. Similarly, increases in the cytosolic levels of calcium in pre-osteoblasts
lead to osteogenesis via the p38 MAPK pathway [62]. As previously discussed, the culture of
MSCs on calcium phosphate surfaces promotes MSC osteogenesis, due to augmented cell
attachment/focal adhesions and the dissolution of the material into calcium and phosphate ions
[59, 63]. Specifically, culture on calcium-phosphate ceramics upregulated OC expression in the
absence of chemical osteoinduction factors, likely due to the release of calcium ions from the
ceramics [60]. It is possible that the HAP co-encapsulated with the MSCs in the Exp+HAP
microcapsules released enough calcium ions to promote OC expression, but not enough phosphate
(< 10 mM) to promote OP expression.
4.5.4 Osteogenic Matrix Deposition by Encapsulated MSCs
The osteogenic ECM components calcium and collagen, secreted by encapsulated MSCs,
were quantified for all microcapsule conditions and standardized to microcapsule dsDNA during
the four-week culture period. The collagen content was measured indirectly by quantifying the
microcapsule hydroxyproline content. The calcium content of acellular microcapsules containing
HAP microgranules was subtracted from Exp+HAP and Osteo+HAP microcapsules, so that all
calcium data reported was deposited by encapsulated MSCs. MSCs in Osteo and Osteo+HAP
microcapsules deposited significantly more calcium in the microcapsule system after 3 and 4
weeks, compared to the microcapsules cultured in standard media (P < 0.05, fig. 4.6a). Osteo
microcapsules contained significantly more cell-deposited calcium than Exp+HAP microcapsules
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at week 2. The calcium/dsDNA content of the osteoinduced microcapsules exhibited a significant
upward trend that continued for the four-week culture period. The Exp+HAP microcapsules
exhibited a modest deposition of calcium in the microcapsule system between weeks 1 and 3, but
this was significantly lower than the osteoinduced cultures at week 3 (P < 0.05). The
calcium/dsDNA content of the Exp microcapsules remained unchanged during the four-week
culture period. The hydroxyproline content of the osteoinduced microcapsules increased over the
four-week culture period, and was significantly higher than the Exp and Exp+HAP microcapsules
between weeks 2-4 (P < 0.05, fig. 4.6b). Biochemical analysis suggests that the osteoinduced
MSCs are depositing a calcium/collagen composite, which could be the precursor to a mineralized
matrix found in new bone. Cells can use the microcapsule materials (C4S/chitosan membrane and
HAP microgranules) as a template to begin bone regeneration by first depositing a collagencalcium matrix, that could be further remodeled into bone in vivo.

Fig 4.6: Osteogenic matrix deposition by encapsulated MSCs. (a) Mass of cell-deposited solid calcium content
of capsules normalized to dsDNA. Total calcium mass of acellular HAP capsules was subtracted from Exp + HAP
and Osteo + HAP values for all time points. (b) Mass of hydroxyproline content of capsules normalized to dsDNA.
Hydroxyproline is a unique component of collagen. *= P< 0.05 (N=4) Osteo relative to Exp and Exp+HAP. #=P <
0.05 (N=4) Osteo + HAP relative to Exp and Exp+HAP
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4.5.5 SEM/EDS Analysis of Microcapsule Interior
To better visualize the contents of the microcapsule interior after four weeks of culture,
microcapsules were fixed, lyophilized, and cut in half to expose the contents for SEM/EDS
analysis. Both low magnification (fig. 4.7a-d) SEM images of cut microcapsules in full view, and
higher magnification (fig. 4.7e-h) SEM images of the microcapsule interiors were acquired. Exp
microcapsules had a smooth membrane that appeared to fold/collapse in on itself after cutting,
exposing the interior (fig. 4.7a). SEM revealed cell aggregates attached to the microcapsule wall
in the interior of the Exp microcapsules, surrounded by strands of ECM-like fibrils, possibly
collagen deposited by cells in culture (fig. 4.7e). Osteo microcapsules had a rigid membrane that
partially kept its shape after cutting (the membrane did not fold over), and the membrane had a
rough appearance due to mineral deposition (fig. 4.7b). The Osteo microcapsule interior was full
of loosely organized mineral crystals that covered the microcapsule membrane, and filled most of
the microcapsule space (fig. 4.7f). MSCs were attached to the mineral. Results show that
differentiation of encapsulated MSCs promotes active mineralization that can drastically augment
the microcapsule interior, and fill it with an osteoid-like mineral matrix.
Microcapsules fabricated with HAP microgranules had a substantially different interior
composition than the Exp and Osteo conditions. Exp+HAP membranes appeared relatively
smooth, with some mineral-like nodules present on the interior of the microcapsule membrane
(fig. 4.7c). The microcapsule membranes folded slightly after cutting, likely due to the weight of
the HAP microgranules. Additionally, some of the internal HAP microgranules spilled out onto
the carbon tape after cutting, indicating a lack of ECM deposition by encapsulated MSCs that
could have bound the HAP microgranules together. The interior of Exp+HAP microcapsules
showed encapsulated MSCs had attached to HAP microgranules, and not only aggregated by
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attaching to other cells, like the Exp condition (fig. 4.7g). Similarly, Osteo+HAP microcapsules
appeared relatively smooth on the outside; however, the interior was crowded with encapsulated
MSCs, HAP microgranules and ECM, so it was difficult to observe the interior of the microcapsule
membrane (fig. 4.7d). Unlike the Exp+HAP microcapsules, the interior matter (HAP
microgranules and cells) mostly stayed inside the Osteo+HAP microcapsule interior after cutting.
Encapsulated MSCs were attached and spread around and between HAP microgranules in the
Osteo+HAP condition (fig. 4.7h). Additionally, the Osteo+HAP microcapsules had visibly more
material in the interior of the microcapsules, compared to the Exp+HAP condition.
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Fig 4.7: SEM images of internal capsule extracellular matrix (ECM). (a-d) SEM images of the inner cores of
split capsules after 4 weeks of static culture in standard (Exp and Exp + HAP) and osteogenic (Osteo and Osteo +
HAP) media (scale bar = 100 um). (e-h) Corresponding magnification of (a-d) (scale bar = 10 um). Black arrows
denote cells and cell aggregates, dashed arrows denote fibrillar ECM, * denote HAP microgranules, and # denote
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cell deposited crystalline mineral. (i-l) EDS spectra corresponding to SEM images (e-h), showing relative amounts
of Calcium (Ca), Phosphorus (P), Carbon (C) and Oxygen (O).

Elemental analysis of the microcapsule interior revealed significant differences between the
microcapsule conditions that depended mainly on whether the MSCs were induced to osteogenesis.
EDS spectra for Exp microcapsules showed a low content of Calcium and Phosphorus, relative to
the reference elements Carbon and Oxygen (fig. 4.7i). A similar EDS spectra was observed for
Exp+HAP (fig. 4.7k). Despite the presence of HAP microgranules, the Exp+HAP capsules had a
similar spectrum to the Exp microcapsules. Osteoinductive culture of encapsulated MSCs
produced EDS spectra suggesting encapsulated MSCs actively mineralized the microcapsule
interior with a calcium-phosphorus apatite. The EDS spectrum for Osteo microcapsules showed
significantly higher levels of Calcium and Phosphorus, compared to reference elements (fig. 4.7j).
A similar EDS spectra was observed for the Osteo+HAP microcapsules (fig. 4.7l). Table 4.1 shows
the calcium/phosphorus ratios calculated from the EDS spectra for each microcapsule condition.
Microcapsule formulations containing HAP microgranules had much higher Ca/P ratios than the
conditions without microgranules, and these values (2.16 + 0.21 for Exp+HAP and 2.41 + 0.86 for
Osteo+HAP) were like Ca/P ratios present in cortical bone in vivo [64, 65]. Most of the calcium
and phosphorus present in the Exp+HAP sample likely came from HAP microgranules already
included in the formulation, however it is impossible to separate HAP-associated calcium and
phosphorus from cell-deposited elements in EDS spectra with the current apparatus. Osteo
microcapsules without initial HAP microgranules also showed Ca/P ratios (1.69 + 0.22)
approaching in vivo bone. Data shows that encapsulated and osteoinduced MSCs can deposit a
mineralized ECM with Calcium and Phosphorus content like HAP.
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Table 4.1 Ca/P ratios from EDS analysis of microcapsule interior
A closer SEM analysis of the microcapsule membrane and HAP microgranules in the
microcapsule conditions revealed that actively mineralizing osteoinduced MSCs deposited
substantial mineral on the membranes and microgranules. Acellular microcapsule membranes
exhibit the rough surface of a porous hydrogel, without other materials (fig. 4.8a, g). The Exp
microcapsule membranes appear significantly less porous and more smooth compared to acellular
microcapsules, likely due to protein deposition on the membrane and in the pores during four
weeks of culture (fig. 8b, h). In contrast, the membranes of the Osteo microcapsules are covered
in mineral crystals of two phases: plate-like crystals roughly 1 um across and organized in a
flowerlike configuration, with spherulite crystals found between the plates (fig. 4.8 c, i). The
mineral crystals in the Osteo condition have the same plate and spherulite appearance as HAP
observed in bone, particularly at the mineralization front [66-68]. Moreover, the mineral crystals
on the Osteo membrane resemble those formed on other biomaterial systems containing C4S [69,
70]. Additionally, chitosan has demonstrated ability to nucleate HAP when combined with
polyanionic additives (polyacrylic acid, for example) [71]. The C4S/chitosan polyelectrolyte
capsule membrane serves as a favorable material that supports mineralization by osteoinduced
MSCs.
The osteoinduced MSCs demonstrate a similar ability to modify the surfaces of HAP
microgranules included in microcapsules. Neat HAP microgranules (not modified by
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encapsulation or exposed to cell culture) display smooth facets between the grains of sintered HAP
particles (fig. 4.8d, j). The HAP microgranules in the Exp+HAP microcapsules exhibit slightly
rough (compared to neat HAP microgranules) facets of the microgranules due to protein deposition
over four weeks of culture, but the surface of these microgranules still appears relatively
unmodified. The actively mineralizing MSCs in the Osteo+HAP microcapsules significantly
mineralized the surfaces of the HAP microgranules, and rough spherulite mineral crystals, about
1-2 μm in diameter, are shown protruding off the microgranule surface (fig. 4.8f). Higher
magnification SEM images show the spherulites in the Osteo+HAP condition are composed of
even smaller fused spherulites, 10-30 nm in diameter (fig. 4.8l). The spherulites growing off the
HAP microgranules share similar size and shape characteristics with calcospherulites found in
bone [72, 73]. Interestingly, only the spherulite mineral phase was observed in the Osteo+HAP
microcapsules, while both the plate and spherulite phases were observed in the Osteo
microcapsules. Crystal Nucleation Theory (CNT) suggests (with vindication through experiments)
that the topography of a substrate determines the shape of the crystals nucleated on the substrate,
by augmenting the free energy barrier the system must overcome for nucleation to proceed [74].
Surfaces containing pits, pores or cavities with acute angles and high curvature will decrease the
surface energy cost of nucleation (decreasing surface energy relative to volume of crystal nuclei)
compared with flat and relatively featureless surfaces [75]. Nucleation on a low curvature surface
(such as the smooth surfaces of the HAP microgranules) will produce spherical crystals as the
crystal nuclei seek to decrease their surface energy to volume ratio, to decrease the free energy
barrier to nucleation [74]. In the Osteo+HAP microcapsules, the osteoinduced MSCs are
mineralizing next to the HAP microgranites, causing the bulk of the mineral nucleation to occur
on the HAP microgranule surface in this microcapsule condition. The flat surface of the HAP
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microgranules makes the spherulite crystal the most energetically favorable phase for HAP to
nucleate in this system; in contrast, the porous and rough membrane of the microcapsules provides
several nucleation points that decrease the energy barrier to nucleation, making different (platelike) crystal phase nucleation possible.

Fig 4.8 SEM of Microcapsule Membrane Mineralization. (a-c) SEM images of the interior surfaces of
microcapsule membranes for Acellular, Expansion and Osteo microcapsule conditions. (d-f) SEM images of the
surface of neat HAP microgranules, Exp+HAP microgranules, and Osteo+HAP microgranules. (g-l) Higher
magnification images of a-f.

Another unique feature of the Osteo microcapsule condition was that MSCs migrated out
of the microcapsule interior, and attached and spread on the mineralized exterior of the
microcapsules. SEM analysis demonstrated that some Osteo microcapsules had MSCs growing on
the mineralized exterior, with their lamellipodia spread out in what appear to be focal attachments
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(fig. 4.9a-b). MSC migration and attachment on the exterior of other microcapsule conditions was
not observed. The attachment of the MSCs to mineralized membrane was likely aided by ECM
proteins that adsorbed on the mineralized microcapsule exterior [76, 77]. Moreover, the generation
of a hypoxic environment in the Osteo microcapsule interior could have induced encapsulated
MSCs to migrate to the microcapsules exterior since mineralization of the microcapsule membrane
may have inhibited nutrient diffusion to the microcapsule interior [78]. Because the mineralization
of the Osteo+HAP microcapsules was likely localized to the HAP microgranules, the Osteo+HAP
microcapsule membrane maintained sufficient porosity so that normoxic conditions were
maintained.

Fig 4.9 SEM of Cell Attachment on Osteo Microcapsules. (a) SEM image of cells attached and spreading on
outer wall of Osteo microcapsules. (b) Higher magnification image of (a). Arrows denote attached cells.

4.5.6 Analysis of Growth Rate of Encapsulated MSCs
The SEM results show in some conditions, particularly the Osteo microcapsules, the
capsule interior and capsule membrane may mineralize to such an extent that the mineral restricts
nutrient flow to the encapsulated cells and restrict their proliferation. The results of alamarBlue®
reduction (fig. 4.10a) show for Exp, Exp+HAP, and Osteo+HAP microcapsules, the percent
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reduction of alamarBlue® generally increased over weeks 1-4 of culture, indicating more
metabolic activity and (likely) a higher cell number in the microcapsule cultures after 3 weeks in
culture. Interestingly, it appears that the percent reduction of alamarBlue® plateaus or slightly
decreases after the second week of culture, indicating either no cell growth, a decrease in cell
metabolism, or possible cell death. Calculation of the specific growth rate (fig. 4.10b) demonstrates
that cells encapsulated in Exp had a similar growth rate over all 3 weeks of culture. Cells
encapsulated in Exp+HAP and Osteo+HAP microcapsules appeared to show a decrease in specific
growth rate during the 3 weeks of rotary culture, but the differences were not significant between
each week. Interestingly, cells in the Osteo microcapsules had a significantly lower growth rate
between weeks 2-3 than weeks 1-2 of culture (-0.010+0.036 day-1 vs. 0.13+0.036 day-1,
respectively), again indicating decrease in cell metabolism or possible cell death. Moreover, the
Osteo growth rate between weeks 2-3 was significantly lower than the Exp microcapsules. The
decrease in growth rate in Osteo microcapsules occurs at a similar time point with the microcapsule
membrane mineralization observed from tetracycline fluorescence, and mineralization observed
in SEM analysis of microcapsules. Analysis of the encapsulated cell growth rate suggests that
microcapsule membrane mineralization may inhibit cell proliferation in Osteo microcapsules. The
Osteo+HAP microcapsules did not show such pronounced decrease in cell growth rate, possibly
due to lack of mineralization of microcapsule membrane (and preferential mineralization of HAP
microgranules, discussed previously).
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Fig 4.10 Growth rate of encapsulated MSCs exposed to medium flow. (a) Percent reduction of alamarBlue®
over 3 weeks of rotary culture. (b) Specific growth rate computed from alamarBlue® reduction. * (P < 0.05) Osteo
significantly different from previous time point. # (P < 0.05) Osteo significantly different from Exp at same time
point.

4.6 Summary and Discussion:
For this first step in the characterization of the modular platform, we demonstrated that the
microcapsule materials 1) maintain MSC viability and limited proliferation in static culture, 2)
facilitate MSC osteogenesis, and 3) facilitate deposition of an osteoid/mineralized matrix within
the microcapsule interior. The GAG/Chitosan/HAP microcapsules support encapsulated MSC
viability over at least four weeks of static culture, and that viability is maintained during osteogenic
induction of and subsequent mineralization by MSCs. The microcapsules facilitate osteogenesis
of encapsulated MSCs as evident by the temporal secretion of early (ALP) and late (OC and OP)
biomarkers for MSC differentiation to osteoblasts. Additionally, the osteogenesis promotes
deposition of a calcium and collagen rich bone-like ECM, as well as mineral deposition within the
microcapsule interior. Differentiating MSCs deposited mineral on the microcapsule membrane and
encapsulated HAP microgranules. Interestingly, the morphology of the cell-deposited mineral
depended on the substrate of mineral nucleation, which can be explained by CNT. Furthermore,
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the C4S/chitosan microcapsule membrane proved a suitable substrate for mineral growth by
actively mineralizing MSCs.
The four-week culture period used to generate in vitro tissue engineered bone
microcapsules introduces significant lead time that would not be practical for clinical applications.
However, this in vitro characterization of encapsulated MSC osteogenesis and bone-like ECM
deposition validates the use of the microcapsules with the current GAG/Chitosan/HAP formulation
as the basis for a bone regeneration platform. The base microcapsule materials, C4S and chitosan,
have demonstrated Osteoinductive capability in vitro and in vivo, and chitosan has exhibited the
potential to nucleate HAP when combined with a suitable polyanion [71]. Our in vitro results
suggest that the combination of HAP and C4S can promote MSC osteogenesis to a limited degree,
a feature also noted in the literature. These phenomena strongly suggest that the
GAG/Chitosan/HAP microcapsules would regenerate bone in vivo if implanted with a suitable preosteoblast cell type. Moreover, the combined pro-angiogenic effects of C4S and chitosan [79-81]
could promote the rapid vascularization of a GAG/Chitosan/HAP microcapsule construct after in
vivo transplant in a bone defect.
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CHAPTER 5: ANALYSIS OF MINERAL ARCHITECTURE ON FUSED
CONSTRUCT MECHANICAL PROPERTIES
5.1 Introduction
A bone regeneration platform must replace the natural skeletal support and resistance to
compression properties of natural bone. Ideally, the regeneration platform would have mechanical
properties similar to native bone immediately upon implantation; however, this is more difficult
with a modular system that uses cells to facilitate implant integration, as this often requires some
initial soft-tissue component to be implanted with the hard tissue. In this chapter, fused constructs
were fabricated from microcapsules, and the mechanical properties of the fused constructs were
evaluated with respect to microcapsule mineralization from 4 weeks static culture, and for the
effects of HAP microgranules. Additionally, the overall mineral density of fused constructs, as
well as the density of the deposited mineral phase, were quantified and used to elucidate the effects
of mineralization on fused construct mechanical properties. Results from this chapter will allow
us to evaluate the mechanical properties a fused construct would have immediately upon
implantation, and to estimate how a fused microcapsule construct would perform after
mineralization in vivo.
5.2 Aim and Rationale:
The main specific aim of this chapter is to characterize how active mineralization of the
microcapsules and HAP microgranules by the encapsulated MSCs influences the mechanical
properties of fused microcapsule constructs. Additionally, the overall mineral density of the fused
constructs, as well as the density of the mineral itself, will be characterized, and their relation to
the mechanical properties of the fused constructs will be discussed. The rationale for this aim, is
that examining the mineralization of the microcapsules in response to both MSCs and HAP
microgranules in the capsule formulation will allow us to hypothesize how the mechanical

53

properties of our material will perform upon mineralization in vivo. Additionally, characterizing
the mechanical properties in response to mineral organization and architecture will facilitate
development and design considerations to optimize the materials included in the microcapsule
formulation, and whether actively mineralizing cells are necessary for mechanical property
enhancement. This aim is significant, because it will allow us to determine if our bone regeneration
platform can approach the mechanical properties of native bone, and hypothesize whether
improvements in microcapsule mineralization will affect mechanical properties of the fused
constructs. Characterizing the response of fused construct mechanical properties to microcapsule
mineralization will allow us to proceed with modifications of the microcapsule system that can
enhance vascularization, and possibly bone regeneration, in vivo.
5.3 Experimental Approach:
Study 1: Evaluation of Mineralized Fused Construct Mechanical Properties.
Fused constructs were fabricated from microcapsules cultured for four weeks in static conditions,
and the effects of active mineralization and/or HAP microgranules on fused construct elastic
moduli and compressive yield point were evaluated.
Study 2: Quantification and Analysis of Fused Construct Mineral Density and Bone Volume.
The overall mineral density and organization of mineral in fused constructs was evaluated via
MicroCT imaging, and the influence of HAP microgranule and osteogenic culture on mineral
density and organization were evaluated. Results were used to better understand how microcapsule
mineral content affects fused construct mechanical properties.
Study 3: Examine the Organization and Architecture of Mineral on Microcapsule Membranes.
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Mineralization on the microcapsule membrane was analyzed via SEM and EDS, and results were
used to better understand how the location of mineral within the microcapsule (on the membrane
vs. in the bulk interior) affects the mechanical properties of the fused constructs.
5.4 Materials and Methods:
5.4.1 Fused Construct Assembly
Microcapsules from all conditions were cultured for four weeks (same conditions as 4.4.2),
and subsequently assembled into fused modular constructs via a polyelectrolyte deposition
between packed capsules (summarized in fig. 5.1). After four weeks, microcapsules were removed
from culture, rinsed with 37 ºC PBS, and reloaded with a dilute polyanion solution (0.4%
C4S/0.15% mCMC). After reloading, the microcapsules were transferred to a cylindrical mold
with a mesh base (70 μm pore size). After draining excess polyanion solution, the mold was
perfused with dilute chitosan (0.06% w/v) solution at a rate of 1 ml/min. The chitosan solution was
drained, and the fused construct was further perfused with dilute polyanion and subsequently with
0.9% saline to remove unreacted polymers. The fused constructs were carefully removed from the
mold, and placed in 0.9% saline at room temperature to await compressive mechanical testing.
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Fig 5. 1 : Assembly of microcapsules into a fused construct. This fusion method yielded self-supporting fused
constructs, even when the microcapsules contained heavy (relative to the polyelectrolyte complex) HAP
microgranules.

5.4.2 Mechanical Testing of Fused Constructs
Compression of fused constructs between parallel plates was performed on an MTS bionix
100 mechanical testing apparatus (MTS Systems Corporation, Eden Prairie, MN), with a constant
strain rate of 0.1mm/min until failure in a 0.9% saline bath, as per literature and ASTM standards
[82, 83]. Data was used to construct representative stress-strain plots, average yield compressive
stresses, and elastic moduli for fused microcapsule constructs after 4 weeks of static osteoinductive
or standard culture. The yield point will be defined as the point of transition from the elastic
deformation (linear stress-strain behavior) to plastic deformation (non-linear behavior), and
determined by reporting the stress value at a 0.2% strain offset. The elastic modulus will be
calculated from the slope of the elastic portion of the stress-strain curve.
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5.4.3 MicroCT Analysis of Fused Mineralized Constructs
After four weeks of static culture, microcapsules from all four conditions will be fused via
the methods discussed previously, fixed in 10% neutral buffered formalin (NBF), and imaged via
micro computed tomography (µCT). Acellular microcapsules containing HAP microgranules
(referred to as Acellular HAP) will be fused and imaged as well, as a “blank” to differentiate
between cell-deposited mineral, and HAP mineral already present in HAP microcapsules. Fused
constructs were imaged in solution (sterile PBS/30% (w/v) sucrose as cryoprotectant) using µCT
(µCT40, Scanco Medical, Brüttisellen, Switzerland) at 45 kVp, 177 µA (8W), 250 ms integration
time, with a resultant isotropic voxel size of 8 µm. Image sets were calibrated to a series of known
hydroxyapatite (HA) concentrations and processed with a Gaussian noise-reduction filter (σ = 1.2,
support = 2). Each construct was manually outlined and a threshold of 75 mg HA/ccm was utilized
for segmentation. The construct volume (TV), the bone/mineralized tissue volume (BV), bone
volume fraction (BV/TV), apparent bone mineral density (BMD), and inherent bone tissue mineral
density (TMD) were calculated using on-board Scanco software. BMD refers to the combined
density of the hard and soft (mineral and hydrogel/ECM/cell body) components of the fused
microcapsule constructs, and TMD refers to the density of the hard tissue components only. The
BV/TV from Fused Acellular HAP microcapsules will be subtracted from the Exp+HAP and
Osteo+HAP, to report data on cell-deposited mineral that contributes to BV/TV results.
5.4.4 SEM Analysis of Mineralized Membrane Cross-Section
The interior of the microcapsules was assessed via SEM in a protocol similar to section
4.4.6. After four weeks of culture, microcapsules were rinsed with PBS and fixed in 2.5% (v/v)
glutaraldehyde/0.1 M cacodylate buffer (pH = 7.4) for 24 hrs at 4 C. The fixed microcapsules were
then washed twice with PBS to remove glutaraldehyde, equilibrated with DI water for three
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changes, frozen with liquid nitrogen, and lyophilized for 48 hours. After lyophilizing, the
microcapsules were cut with a razor blade under a microscope to expose their cross-sections, and
examined with SEM coupled with EDX spectrometry (JEOL 7600 FESEM, JEOL USA, Inc.,
Peabody, Massachusetts). For this study, special attention was given to high magnification analysis
of the microcapsule membrane, as the bulk of the microcapsule interior was analyzed in section
4.5.5.
5.4.5 Statistical Analysis
Statistical analysis was carried out using GraphPad Prism software. All statistical
comparisons were made by performing a one-way analysis of variance (ANOVA), followed by
Bonferroni’s multiple comparison tests to evaluate significance between two data sets at a time
and correct for false positives of significance. P values less than 0.05 or 0.10 (for microCT
analyses) were considered statistically significant. All data is reported as the mean + standard
deviation.
5.5 Results:
5.5.1 Compressive Mechanical Properties of Fused Microcapsule Constructs
Acellular microcapsules were fused into porous cylindrical constructs via the process
depicted in fig 5.1, without exposure to culture medium, and their hydrated stress-strain
mechanical properties were tested under uniaxial compression. Representative stress-strain curves
for the acellular microcapsules are shown in fig. 5.2a (Empty and HAP microcapsules), and fig.
5.2b (Empty microcapsules only). The Empty microcapsules contained no load bearing element
other than the polyelectrolyte microcapsule membrane, and the HAP microcapsules contained
HAP microgranules as a reinforcement against compression. Thus, it is not surprising that the HAP
microcapsules exhibited a noticeably higher average yield stress compared to empty microcapsules
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(446.2 + 27.4 kPa and 5.9 + 1.1 kPa, respectively, fig. 5.2c). Results show that fused constructs
containing HAP microgranules, without any additional mineral content, can provide some
resistance against compression. Unfortunately, the yield stress of the HAP microcapsules falls
short of native bone (131-205 MPa) [84]; moreover, the significant resistance to compression
occurs after the constructs have been compressed roughly 50% of their height. The initial lack of
resistance to compression during the test is likely due to water quickly evacuating the fused
construct into the surrounding water bath, since all compression tests were unconfined (as per
ASTM standards). Additionally, the microcapsules contained significant void space, even when
HAP microgranules were included: recall from Chapter 4 that the maximum HAP microgranule
content in the GAG solution that could be extruded to create microcapsules was 50% (v/v). The
mechanical properties of the fused microcapsule constructs may be enhanced significantly if either
more mineral was deposited in the void space in the microcapsule interior, or if the mineral was
organized in such a way that it reinforced the microcapsule membrane to keep it from collapsing
during the initial stages of compression. The rest of this study will focus on mechanical properties
of fused constructs composed of microcapsules with an interior mineralized by osteogenic MSCs,
as a model of how the microcapsules could perform when mineralized in vivo.
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Fig 5.2: Compressive mechanical properties of acellular fused constructs. (a) Representative stress-strain
curves for Empty and HAP microcapsule constructs, and (b) representative curve of Empty microcapsule constructs
only. (c) Average yield point for both Empty and HAP microcapsule constructs.

To evaluate the effects of mineralization on fused construct mechanical properties,
microcapsules containing MSCs were cultured for four weeks in osteogenic or standard media,
and their hydrated stress-strain mechanical properties were tested under uniaxial compression.
Representative stress-strain graphs of fused constructs demonstrate how active mineralization
produced much more mechanically robust fused constructs (Fig. 5.3a). Both Osteo and
Osteo+HAP fused constructs were capable of withstanding higher compressive stress at lower
strains than both Exp+HAP (fig. 5.3b) and Exp (fig. 5.3c). The average yield point of actively
mineralized microcapsules was significantly higher than either of the non-mineralized
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microcapsule conditions (P < 0.05, fig. 5.4a). Moreover, the Osteo fused constructs had a
significantly higher yield point (6.4 + 2.8 MPa) than Exp+HAP fused constructs (0.5 + 0.3 MPa),
despite the inclusion of HAP microgranules in the Exp+HAP constructs (P < 0.05). There was no
statistical difference in the average yield point between the Osteo and Osteo+HAP (6.4 + 2.8 MPa
and 10.4 + 4.4 MPa, respectively) fused constructs (P < 0.05). The Exp+HAP fused constructs had
a significantly higher average yield point than the Exp constructs (0.5 + 0.3 MPa and 0.006 + 0.001
MPa, respectively, P < 0.05). Furthermore, osteoinduction of the microcapsules significantly
enhanced the elastic modulus of the fused constructs. The elastic modulus of the Osteo (43.9 +
36.0 MPa) and Osteo+HAP (42.9 + 34.6 MPa) fused constructs was significantly higher than
constructs formed from the Exp (0.022 + 0.011 MPa) and Exp+HAP (2.9 + 0.4 MPa)
microcapsules (P < 0.05, fig. 5.4b). Like the average yield point, there was no statistical difference
in the elastic modulus between the Osteo and Osteo+HAP constructs. The Exp+HAP fused
constructs also had a significantly higher elastic modulus than the Exp constructs (P < 0.05).
Mechanical property results demonstrate that including HAP microgranules in the microcapsules
can significantly enhance fused construct mechanical properties; however, microcapsule
mineralization by osteoinduced, encapsulated MSCs drastically improved the mechanical
properties of fused constructs, even without the aid of HAP microgranules.
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Fig 5.3: Representative compressive mechanical properties of fused microcapsule constructs. (a) All
representative compressive stress vs. strain curves for each condition. (b) Magnified compressive stress curve for
Exp + HAP wk 4 constructs. (c) Magnified compressive stress curve for Exp wk 4.

The mechanical property improvements in Osteo microcapsules likely stem from
mineralization of the microcapsule membrane itself, rather than just mineral deposition around cell
aggregates in the microcapsule interior. The actively mineralizing MSCs in the Osteo
microcapsules may modify the polyelectrolyte membranes into a calcified-polyelectrolyte
composite, transforming the microcapsules from soft polyelectrolyte hydrogel microcapsules, into
microcapsules with a tougher calcified shell. The subsequent sections of this chapter will explore
the organization and density of mineral in fused constructs composed of mineralized capsules.
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Fig 5.4: Average mechanical properties of fused microcapsule constructs. (a) Average yield point for fused
constructs composed of microcapsules from 4 weeks of static culture in either osteoinduced (Osteo, Osteo+HAP)
or standard (Exp, Exp+HAP) medium. (b) Elastic modulus of fused capsule constructs under compression. @ = No
statistical difference between conditions. * = P < 0.05 (N=4) relative to Exp+HAP.

5.5.2 MicroCT Analysis of Fused Microcapsule Construct Mineral Density
MicroCT analysis of fused microcapsule constructs at a threshold of 75 mg HAP/cm3 or
greater density, revealed mineral content in the Exp+HAP, Osteo, and Osteo+HAP fused
constructs assembled from microcapsules cultured for four weeks. The 75 mg HAP/cm3 was
chosen as a limit to distinguish sparse/immature mineral from surrounding hydrogel/tissue [85,
86]. No radiopaque mineral data was detected for the Exp microcapsules. The MicroCT images
demonstrate (fig 5.5) that all microcapsules containing either HAP microgranules or cell-deposited
mineral contained some mineral above the 75 mg/cm3 density threshold for immature bone.
Moreover, the microcapsules containing HAP microgranules in the formulation (Exp+HAP and
Osteo+HAP) exhibited more overall mineralization than the microcapsules relying only on active
mineralization by encapsulated MSCs (Osteo). Additionally, the Oste+HAP and Exp+HAP fused
constructs appear to have more homogenously-distributed mineral throughout (fig. 5.5 e- f, h-i),
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compared to the Osteo constructs (fig 5.4b-c). The microCT reconstructions demonstrate that the
inclusion of HAP microgranules in the microcapsule formulation produces fused constructs with
more homogenous mineral content. During microcapsule fabrication, a well-mixed
GAG/HAP/MSC slurry will ensure that the droplets (and resulting microcapsules) extruded into
chitosan will have relatively similar amounts of HAP microgranules. Because the HAP
microgranules are much more dense than mineral deposited by osteoinduced MSCs in vitro (at
least over the 4-week time period discussed here), the presence of HAP microgranules contributes
the most to overall fused construct mineral content, exhibited by the more homogenous
mineralization apparent in the Osteo+HAP fused construct (fig. 5.4d-f) compared to the Osteo
fused construct (fig. 5.4a-c). It’s interesting that the Osteo fused constructs had significantly higher
compressive mechanical properties compared to the Exp+HAP constructs, despite the obvious
lower overall mineral density. The increased mechanical properties may be a function of mineral
organization, and not merely mineral content, in the fused microcapsule system discussed here.
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Fig 5.5: Micro CT reconstruction of fused constructs at 75 mg HAP/cm3 threshold. (a-c) Osteo fused
constructs, (d-f) Osteo+HAP fused constructs, and (g-i) Exp+HAP fused constructs. Mineral appears as gray (less
dense) to white (most dense mineral) in reconstructed images.

A higher magnification look at the fused constructs elucidates differences in mineral
organization in the microcapsule systems with and without HAP microgranules. Cutaways of 3D
reconstructions of Osteo fused constructs demonstrate that actively mineralizing MSCs deposited
radiopaque mineral that mostly nucleated around the C4S/chitosan membrane (fig. 5.6a-b). The
cutaway shows the roughly spherical mineralized membranes of the Osteo microcapsules packed
together in the fused construct (fig. 5.6b). Smaller points of mineralization, possibly not directly
nucleated on the microcapsule membrane, are also present. The HAP microgranules included in
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the Osteo+HAP condition were the dominant tomographic feature, shown as bright aggregates in
the 3D cutaway (fig. 5.6c). Less intense tomographic material was present around the HAP
microgranules, indicating cell-mediated mineralization around the HAP microgranules and
microcapsule interior (fig. 5.6d). Unlike the Osteo microcapsules, it appears cell-deposited mineral
nucleated around the already present HAP microgrnaules in the Osteo+HAP formulation. Fused
Exp+HAP microcapsule constructs exhibited well-defined points of tomographic material from
the HAP microgranules originally included in the Exp+HAP formulation (fig. 5.6e-f). The absence
of any tomographic material between these bright, well-defined points suggests that any cellmediated mineralization of these microcapsules was significantly less dense (below the 75 mg
HAP/cm3 threshold) than the actively mineralized Osteo and Osteo+HAP conditions. The closer
look at the organization of mineral in the microcapsules indicates differences in organization,
depending on the presence of HAP microgranules during microcapsule fabrication. This difference
in mineral organization likely affects the overall mechanical properties of fused microcapsule
constructs, as the strategic location of mineral to the microcapsule membrane, for example, can
better reinforce the microcapsule membranes against compression, compared to loose mineral.
MicroCT analysis showed that active mineralization by osteoinduction of encapsulated
MSCs contributes to the overall hard tissue volume above the 75 mg/cm3 threshold after the fourweek culture period (fig. 5.7). The Osteo+HAP fused constructs exhibited the highest overall
BV/TV (0.52 + 0.012) of the cultured microcapsule conditions, and this was significantly higher
than the Exp+HAP (0.24 + 0.15) (P < 0.1) and Osteo (0.067 + 0.028) (P < 0.05) fused constructs.
There was no statistical difference between the overall BV/TV of Acellular HAP and Osteo+HAP
constructs. As previously discussed, the HAP microgranules make the most significant
contribution to the overall BV/TV of the fused microcapsule constructs, if they are included during
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microcapsule fabrication. When the cell-deposited BV/TV was assessed (BV/TV of Acellular
HAP was subtracted from Exp+HAP and Osteo+HAP, fig. 5.7b), microCT analysis shows that
actively mineralizing MSCs in both Osteo and Osteo+HAP constructs deposited similar levels of
mineral above the 75 mg HAP/cm3 detection threshold (0.067 + 0.028 and 0.091 + 0.012,
respectively). Interestingly, the Exp+HAP had significantly less bone volume density than the
acellular fused microcapsules constructs, as shown by the negative BV/TV value for the Exp+HAP
after subtracting the fused construct blanks (-0.19 + 0.15).

Fig 5.6: Higher magnification of microCT reconstruction of mineralized fused constructs. Images show cross
sections of (a) Osteo, (c) Osteo+HAP, and (e) Exp+HAP fused constructs, along with higher magnification images
of the inset in (b), (d) and (f), respectively.

MicroCT analysis was also used to investigate the density of the hard tissue/mineral
components of the fused microcapsule constructs, or the Tissue Mineral Density (TMD). All fused
microcapsule constructs had similar TMD (233.1 – 330.9 mg/cm3), and there were no statistical
differences among the conditions (fig. 5.7c). The constructs containing HAP microgranules would
demonstrate high TMD values, due to the dense HAP microgranules included in these
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formulations; however, the high density of the cell-deposited mineral in the Osteo fused constructs
(233.1 + 94 mg HAP/cm3) was an interesting find. The osteoinduced MSCs deposit and remodel
mineral into a similarly dense material as the HAP microgranules (307.5 + 30 mg HAP/cm3 for
Acellular fused constructs). The TMD values for Osteo+HAP and Exp+HAP were similar (291.7
+ 16.3 and 330.9 + 32.6 mg HAP/cm3, respectively). Cortical bone has a significantly higher TMD
of 1200 + 53 mg HAP/cm3 [87]. Of course, the BMD (mineral density of entire construct,
including non-mineral components, fig. 5.7d) of all fused microcapsule constructs mirrors the
overall BV/TV trend (fig. 5.7a), with the fused constructs containing HAP microgranules
exhibiting higher BMD than the Osteo fused construct. The Osteo+HAP fused constructs had the
highest BMD at 125.1 + 13.7 mg HAP/cm3, but this is substantially lower than the average human
BMD for cortical bone of 271 – 439 mg HAP/cm3 [88]. Again, because the HAP microgranules
contribute significantly towards the mineral density of the entire tissue volume, it is expected that
the Acellular HAP, Exp+HAP and Osteo+HAP would have higher BMD than the Osteo fused
constructs. These results indicate that an optimal microcapsule design for bone regeneration should
include synthetic (or allogenic) bone mineral that closely matches the TMD of human bone, and
as much mineral should be included in each microcapsule to increase the BMD to levels similar to
human bone. Additionally, the results indicate that the osteoinduced MSCs deposit a mineral that
is at least as dense as the synthetic HAP microgranules, and this mineral contributes to the
compression resistance observed in Osteo fused constructs.
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Fig 5.7: Mineral density of fused constructs. (a) Overall Bone Volume/Total Volume of fused constructs. (b)
Cell deposited Bone Volume/Total Volume of fused constructs, determined by subtracting the BV/TV for Acellular
HAP constructs from overall BV/TV for Exp + HAP and Osteo+HAP constructs. (c) Total Mineral Density (TMD)
of fused constructs, and (d) Bone Mineral Density (BMD) of fused constructs. (N = 3) # P < 0.1 relative to
Exp+HAP, * P < 0.05 relative to Osteo. @ P < 0.1 no statistical difference between conditions.

The significantly lower BV/TV of Exp+HAP fused constructs after 4 weeks of culture
compared to freshly made acellular microcapsules with HAP microgranules is unexpected, and is
likely due to the following factors. To form Exp+HAP microcapsules, the GAG/HAP slurry is
mixed with a cell precipitate prior to encapsulation, while the GAG/HAP slurry is encapsulated
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without additions to fabricate Acellular HAP microcapsules: the addition of cells (a soft tissue
component) to the Exp+HAP microgranules dilutes the amount of HAP microgranules that can be
included per microcapsule during encapsulation. Essentially, the Exp+HAP fused constructs will
be composed of less minerally-dense microcapsules, because these microcapsules contain MSCs
and HAP microgranules. Moreover, the MSC pellet would have contained some residual culture
medium from the cell suspension after centrifugation, which would have affected the concentration
of polyanion in the C4S/HAP/MSC suspension. The change in polyanion concentration would
have affected the formation of the polyelectrolyte microcapsule membrane, and could have
changed the swelling/stretching dynamics in the Exp+HAP microcapsules, compared to acellular
microcapsules. Additionally, static culture of the Exp+HAP may have partially eroded the HAP
microgranules, so that some of the HAP microgranule tomographic volume was under the 75 mg
HAP/cm3 threshold after four weeks of culture. The lysozymes in the culture medium (from the
FBS) may have partially degraded the microcapsule membrane (lysozyme degrades the chitosan
portion), causing the membrane to partially stretch after 4 weeks in culture and increasing cultured
microcapsule volume compared to fresh microcapsules [89]. It is also possible that the
microcpasules in the Exp+HAP fused constructs were less densely packed than freshly prepared
microcapsules, leading to higher total volumes of construct: the microcapsules were settled by
gravity in the capsule fusion apparatus, and the Osteo+HAP microcapsules would certainly be
heavier, due to the added mineral from differentiating MSCs. The following parameters listed
above introduce significant variations when comparing microCT data for cell-containing fused
constructs with Acellular microcapsules to elucidate cell-deposited mineral contributions to
BV/TV of fused constructs. Regardless, the microCT data shows that cells deposit a dense mineral
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with a TMD value close to the HAP microgranules included in the microcapsule formulation, and
that HAP microgranules have the greatest effect on overall TMD and BMD of fused constructs.
5.5.3 Mineral Architecture of Osteo Microcapsule Membrane
After the mechanical property analysis of the fused constructs suggests that the cellmediated mineralization controls the overall compressive mechanical properties of fused
microcapsule constructs, and the microCT reconstruction images show that highly dense mineral
appears to be localized to the microcapsule membrane, we further characterized the mineral
architecture of the Osteo microcapsule membranes via SEM. A cross-section SEM image of the
Osteo microcapsules shows how the rigid, mineralized microcapsules retained their shape after
cutting for SEM (fig. 5.8a). Additionally, a closer magnification on the inner surface of the
microcapsule interior shows the rough, plate-like mineral crystals covering the interior (fig. 5.8b).
When attention is turned to the cross-section area showing the microcapsule membrane, we see
the relatively thin microcapsule membrane supporting a thick layer of mineral crystals, jutting
from the membrane into the microcapsule interior (fig. 5.8c). This mineral layer had an average
thickness of 4.8 + 0.9 μm (n=3), and appeared to cover most of the interior surface of the Osteo
microcapsules. Moreover, EDS analysis of the mineral on the Osteo microcapsule interior
demonstrated the cell-deposited mineral had a Ca/P ratio similar to rat cortical bone [64]. In
contrast, the surfaces of the Exp microcapsules were relatively featureless (fig. 5.8d), save for the
porous C4S/chitosan membrane (fig. 5.8e). Additionally, the Exp microcapsule membranes
couldn’t support their own weight after the microcapsules were cut in half, and the membrane
folded in on the microcapsules. Results indicate that the cell-deposited mineral in the Osteo
microcapsules localizes primarily on the microcapsule membrane, and is of a similar quality (Ca/P
ratio) to native rat cortical bone: it’s likely this mineral organization and architecture that gives the
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Osteo fused constructs a resistance to compression and elastic modulus similar to the Osteo+HAP
fused constructs.

Fig. 5.8: Analysis of mineralization of microcapsule interior via SEM. (a) Macroscopic SEM view of
mineralized interior of Osteo microcapsule. (b) Calcium phosphate mineral crystals nucleated and growing off of
the interior of the Osteo microcapsule membrane. (c) Cross-section of microcapsule membrane edge showing thick
mineral layer in interior. (d) Macroscopic SEM view of non-mineralized Exp microcapsules. (e) High magnification
view of Exp interior membrane.
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Table 5.1: EDS Analysis of Microcapsule Membranes compared to Rat Cortical Bone. Data for Rat Cortical
bone obtained from [64].

After four weeks of osteoinduction culture, the encapsulated MSCs transform the Osteo
microcapsules into calcified, compression-resistant spheres, with a relatively thick mineral shell.
When these Osteo microcapsules are fused together to create a construct, the mineralized
microcapsule membrane imparts significant resistance to compression for the entire construct,
regardless of the lack of HAP microgranules in the interior. The organization of the mineral to the
membrane of the Osteo microcapsules contrasts with the Osteo+HAP microcapsule condition: the
SEM analysis in section 4.5.5 suggests that osteoinduced MSCs deposit mineral around and inbetween HAP microgranules. Regardless, it is difficult to obtain a clear view of the microcapsule
membrane in the Osteo+HAP SEM images, because the HAP microgranules and ECM obscure
the interior of the membrane. The visible parts of the Osteo+HAP interior microcapsule membrane
are relatively featureless compared to the Osteo membrane after 4 weeks of culture.
The mineralization of the C4S/chitosan microcapsule membrane could occur by several
mechanisms. Encapsulated MSCs form aggregates that attach to the microcapsule wall early (see
Chapter 4), and appear to remain attached for the duration of the microcapsule culture and
osteoinduction. Research demonstrates that osteoblasts secrete vesicles containing amorphous
calcium phosphate, that are released to the extracellular space [90]. Fig 5.9 shows several
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mechanisms of vesicle-based mineralization. In one mechanism, intracellular vesicles accumulate
calcium phosphate from mitochondria, and are exported to the extracellular space: alternatively,
vesicles bud off from the osteoblast membrane, and accumulate calcium and phosphate ions (aided
by vesicle-associated enzymes, like ALP) as they travel through the extracellular space [91].
Regardless of how the vesicles are loaded with calcium phosphate, the vesicles will travel through
the extracellular space and nucleate HAP mineral upon contact with a suitable substrate. As
previously discussed, C4S and chitosan are capable of mineralization by nucleating calcium and
phosphate [69, 70, 92]. Additionally, osteoinduced MSCs deposit collagen, which promotes
calcium phosphate nucleation and mineralization in vivo [93, 94]. While MSCs are osteoinduced
during microcapsule culture, they release mineralizing vesicles in 360º, and enough of these
vesicles contact the C4S/chitosan membrane and deposited collagen matrix that the microcapsule
membrane becomes relatively homogenously mineralized over the 4 week culture period. Results
demonstrate that the materials in the microcapsule design facilitate robust mineralization via
encapsulated MSCs through a vesicle-based mechanism, and this mineralization could likely be
duplicated in vivo by vesicle-secreting osteoblasts near a bone injury site, or by osteoinduced
MSCs implanted within the microcapsules.
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Fig. 5.9 Mechanisms of osteoblast ECM mineralization by vesicles. Diagram shows osteoblasts secreting
vesicles containing calcium phosphate, which nucleate to form mineralized HAP on the ECM in developing bone.
Image taken from [90]

5.6 Summary and Discussion:
Analysis of the compressive mechanical properties of the fused microcapsule constructs
show that active mineralization by osteoinduced MSCs significantly enhances the compressive
yield stress and elastic moduli of the fused constructs. This is somewhat intuitive; however, it was
interesting to find that mineralization of the microcapsule membrane in microcapsules without
HAP produced mechanical property improvements similar to microcapsules fabricated with HAP
microgranules. Regardless, the addition of HAP microgranules to the microcapsule fabrication is
beneficial for several reasons, including 1) superior mechanical properties prior to additional
mineralization (compared to empty microcapsules), 2) ease of handling, as the HAP microgranules
cause the microcapsules to settle out of suspension in a solution, and 3) providing a substrate for
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encapsulated MSCs to attach to, which could confer benefits to proliferation and osteogenesis [9597]. Future iterations of the basic microcapsule design discussed here should include some sort of
dense mineral microgranule/interior to enhance encapsulated cell osteogenesis and impart initial
resistance to compression to the microcapsules.
Human bone itself is an anisotropic tissue, and the mechanical behavior (average values of
compressive stress and elastic moduli) varies with the direction of the applied load during
measurement. Additionally, the difference in mineral density and porosity in the trabecular and
cortical regions influence the mechanical properties of the tissue. Table 5.2 provides a summary
of the average mechanical properties of human bone, compared to the fused constructs described
in this study and some other in vitro scaffold systems from the literature. Cortical bone has a
compressive stress and elastic moduli that ranges from 131-205 MPa and 6,000 – 20,000 MPa,
respectively, while trabecular bone has compressive stress and elastic moduli ranges of 5-10 MPa
and 50-100 MPa. Unfortunately, the modular construct with the closest mechanical properties,
Osteo+HAP, falls very short of human cortical bone compressive stress (10.4+4.4 MPa vs. 131
MPa) and elastic moduli (42.9+30.5 MPa vs. 6,000 MPa). The Osteo+HAP fused constructs are
somewhat comparable to the mechanical properties of trabecular bone (5 MPa compressive stress
and 50 MPa elastic modulus). It’s likely that after implantation, the mechanical properties of the
fused construct design proposed here would drastically improve above the values from the in vitro
mineralization, due to exposure to the growth factor milieu encountered in vivo.
Tissue Type
Human Cortical Bone

Compressive Stress
131 - 205 MPa [84]

Elastic Modulus
6,000-20,000 MPa [84]

Human Trabecular Bone
Modular Osteo + HAP (4wk in vitro mineralization)

5-10 MPa [98]
10.4 + 4.4 MPa

50 - 100 Mpa [99]
42.9 + 30.5 MPa

Calcium-Phosphate Alginate Hydrogel
Polycaprolactone – HAP Composite
Poly(D,L-lactic acid-co-glycolic acid) – HAP composite
(6 wk in vitro mineralization)

4 + 0.8 MPa [100]
2.2 + 0.2 MPa [101]
N/A

1200 + 200 MPa [100]
21.4 + 1.4 MPa [101]
18.9 + 8.1 MPa [102]
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Table 5.2 Comparison of Modular Osteo+HAP fused construct mechanical properties to human bone and bone
biomaterials cultured in vitro.

When compared to other bone regeneration systems analyzed in vitro¸ the mineralized
fused microcapsule constructs certainly have competitive mechanical properties. Table 5.2
includes the yield stress and elastic moduli from several published studies for comparison: the
Calcium Phosphate Alginate Hydrogel system is of particular note, since their system combines
human umbilical cord mesenchymal stem cells (hUCMSCs) encapsulated in alginate
microcapsules, embedded in a calcium phosphate bone cement [100]. Compared to this
alginate/cement modular system, the Osteo+HAP constructs have a higher yield stress (4 MPa vs.
10.4 MPa, respectively), while their elastic modulus was significantly larger (1,200 MPa vs. 42.9
MPa), indicating a stiff but brittle system, likely due to the calcium phosphate cement. It should
be noted that the only porosity in the alginate/cement system would occur when the alginate beads
degrade, whereas the modular system presented here has inherent porosity between the fused
microcapsules immediately after fusion, which would likely enhance cell infiltration once
implanted in a bone defect. Several other modular bone tissue engineered systems reported in the
literature do not include data on in vitro mechanical properties for their system, and therefore it is
difficult to comment on how the modular system presented here improves upon these systems
[103, 104].
Interestingly, the microCT analysis revealed that all fused construct formulations that
included HAP microgranules in their formulation had significantly more mineral per volume than
the Osteo microcapsules, yet the Osteo and Osteo+HAP microcapsules had similar elastic moduli
and yield stress. The localization of the mineral to the microcapsule membrane, reinforcing the
membrane against compression, demonstrates that the mineral architecture primarily affects the
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fused construct mechanical properties. Reports from the literature concur that overall mineral
density alone does not determine bone mechanical properties, and properties including porosity,
degree of trabecular interconnectivity, and the plate or rod configuration of mineral also affect the
overall mechanical properties of bone [105-108]. The study presented here adds to the literature
from a biomaterials perspective, and demonstrates with a novel system that it’s not merely the
amount of mineral, but where it’s located within the system, that matters. The ability to influence
mechanical properties of the microcapsule system by localizing mineral to the membrane could
give inspiration for further iterations of the microcapsule design, such as microcapsules containing
HAP microgranules and an exterior calcified shell for added reinforcement.
As discussed in Chapter 4, the four week culture period adds significant lead time for
clinical applications, if the mineralized microcapsules were to be implanted. The mechanical
property analysis discussed in this chapter demonstrates that mineralization by osteoinduced MSCs
significantly reinforces the microcapsule fused constructs against compression: this result should
be replicable in vivo, either through the addition of osteogenic growth factors to the microcapsule
system (BMP-2, etc…), or from the interaction with growth factors secreted physiologically at the
implant site [109]. Moreover, it is likely that tissue ingrowth through the fused construct, combined
with subsequent mineralization in vivo, will significantly enhance the mechanical properties of
fused construct implants, facilitating bone regeneration. The next series of experiments will focus
on examining the host response, tissue regeneration and vascularization in fused constructs
fabricated form microcapsules containing vascularization-enhancing accessory cells in a
subcutaneous model of ectopic bone formation.
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CHAPTER 6: ANALYSIS OF FUSED CONSTRUCT VASCULARIZATION
and TISSUE REGENERATION IN VIVO
6.1 Introduction
Bone is a highly-vascularized tissue, and implants generated from GAG/Chitosan/HAP
microcapsules should ideally vascularize rapidly after implantation to provide nutrients to cells
implanted with the microcapsules, and the facilitate tissue growth into the implant. The ability to
attach and culture accessory cells on the exterior of the microcapsules offers a unique strategy to
control the organization of multiple cell types in an implant. Attaching endothelial-like cells to
microcapsules prior to fusion into a construct will pre-vascularize the construct, and place blood
vessel forming cells in the fused construct pore space. The organization of endothelial-like cells to
the intercapsule pore space of the fused construct can help promote rapid vascularization of the
construct in vivo. This chapter details the process of differentiating MSCs to endothelial
progenitors (EPs) containing some endothelial character and function, and examining how the
attachment of EPs to the exterior of microcapsules containing encapsulated osteoprogenitors (OPs)
influences vascularization of fused constructs in vivo. The in vivo analysis will be conducted in a
rat subcutaneous model, and vascularization will be analyzed via Doppler Ultrasound (US).
Moreover, the tissue infiltration and matrix composition within the implants will be evaluated over
the course of the life of the implants in vivo. The influence of EPs over vascularization, tissue
ingrowth and matrix deposition will be compared to MSCs attached to the microcapsule exterior,
and to microcapsules without accessory cells.
6.2 Aim and Rationale:
The specific aim for this chapter is to characterize the in vivo response to fused constructs
composed of GAG/Chitosan/HAP microcapsules and vascularization-enhancing accessory cells.
Attention will be paid to blood flow and blood vessel construction through implanted constructs.
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The rationale for this aim, is that attaching vascularization-enhancing accessory cells (Endothelial
Progenitors) to the microcapsule exterior will enhance vascularization and new-bone regeneration
in vivo. This aim is significant, because it will provide preliminary data on how our modular bone
graft design with accessory cells performs in vivo with respect to immune response, tissue
regeneration, and vascularization. Confirming that the addition of appropriate accessory cells
enhances the vascularization of the fused constructs in vivo will facilitate later optimization of the
bone graft system, by optimizing cell type and ratio of vascular cells to fused construct volume.
6.3 Experimental Approach:
Study 1: Confirm Accessory Cells can Attach to GAG/Chitosan/HAP Microcapsules
EP cells were generated from MSCs using established protocols, and examined for the expression
of endothelial markers and tube formation in basement membrane. EP cells were seeded on to
GAG/Chitosan/HAP microcapsules and examined for attachment via cell fluorescence and SEM.
This study allows us to confirm that MSCs can be differentiated to EPs that express endothelial
markers, and that GAG/Chitosan/HAP Microcapsules support accessory cell attachment.
Study 2: Examine Blood Flow Through Fused Constructs in vivo via Doppler Ultrasound (US)
Disk constructs formed from fused microcapsules with attached accessory cells were implanted
subcutaneously in the backs of rats, and imaged at 1, 2, and 4 weeks post-surgery via Doppler US
to observe blood flow through the constructs. The microcapsules contained encapsulated
osteoprogenitors (OP) to promote bone formation in the constructs in vivo. The ability of EPs to
enhance construct vascularization will be compared to an MSC control, microcapsules without
accessory cells, and completely acellular microcapsules. This study allows us to characterize blood
flow through the implanted constructs in real time, and investigate whether EPs enhance fused
construct vascularization.
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Study 3: Evaluate Tissue Regeneration in Fused Constructs in vivo via Histology.
After each Doppler US imaging session, implanted constructs will be harvested and assessed for
tissue regeneration via histology. Attention will be paid to the type and organization of matrix,
immune cell response, and blood vessel formation within the implants over the 4-week in vivo
period. This study allows us to confirm that the fused microcapsule system can support in vivo
tissue regeneration without a detrimental immune response, and that the addition of accessory cells
enhances tissue regeneration.
6.4 Materials and Methods:
All materials and reagents used were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise noted, and were of analytical, cell culture grade or higher. Sprague Dawley rats
were purchased from Envigo (Huntington, UK).
6.4.1 Cell culture conditions
MSCs were differentiated to OPs for 3 weeks prior to encapsulation in C4S/chitosan
microcapsules, to promote ECM deposition and possible mineralization in vivo within the
microcapsules. All cells were cultured in a humid atmosphere with 5% CO2 at 37 ºC. MSCs were
induced to osteogenesis using the same method and osteoinduction medium as section 4.4.2: MSCs
were cultured for 3 weeks in L.DMEM supplemented with 10% FBS, 100 nM dexamethasone, 10
mM 𝛽-glycerophosphate, and 50 𝜇M ascorbic acid-2-phosphate. Representative cultures were
stained with Alizarin Red S after 3 weeks of differentiation, and inspected for the presence of redstained mineral nodules to confirm differentiation to OPs. Briefly, 3 weeks after differentiation,
cultures were washed with PBS, fixed in 10% neutral buffered formalin (NBF) overnight, and
washed again with DI water (3x, 5 min each). Cultures were then incubated in Alizarin Red S
working solution (2% (w/v) pH 4.2, adjusted with ammonia) until red lakes began to form on the
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cell monolayer (after 10 minutes), after which the Alizarin Red S solution was aspirated, and
residual staining removed by a brief wash with DI water. Cultures were viewed under brightfield
microscopy for orange/red-stained mineral nodules. Microcapsules were formed via the same
protocol as section 4.4.2., and OPs were encapsulated at a density of 5 million cells/ml C4S/HAP
suspension. Microcapsules with OPs were immediately processed for collagen coating after
encapsulation, described in 6.4.3 below.
6.4.2 Differentiation of MSCs to EPs
MSCs were differentiated to an endothelial lineage (EPs) via an established protocol [110,
111]. MSCs at passage 1 were seeded at 5x103 cells/cm2 and maintained for 10 days in endothelial
differentiation medium, consisting of 100 ng/ml VEGF, 50 ng/ml EGF, 1 μg/ml hydrocortisone,
and 5% FBS in L.DMEM. Differentiation to EPs was validated via assessment of tube formation
in basal membrane (Matrigel ®, Dow Corning, Midland, MI), and immunofluorescent staining of
the common endothelial markers von Willibrands Factor (vWF) and Platelet Endothelial Cell
Adhesion Molecule 1 (PECAM-1). For the Matrigel assay, 50 μl of Matrigel was gelled in each
well of a 96 well plate. EPs were trypsinized after 10 days of endothelial differentiation, and plated
at a density of 5x103 cells/cm2 onto the surface of the Matrigel. The ability of the EPs to form tubelike networks on Matrigel was assessed between t=0 (when the cells were plated) and t=12 hrs. If
MSCs were properly differentiated to EPs, these EPs should form tube-like networks in the
absence of angiogenic growth factors like VEGF [110, 111]; so, EPs were seeded onto the Matrigel
in standard medium (L.DMEM+5% FBS) without VEGF supplement. MSCs seeded in standard
medium served as a negative control, and MSCs seeded in medium supplemented with 50 ng/ml
VEGF served as a positive control.
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For PECAM-1 and vWF staining, cells grown on plastic were washed with PBS, and
permeabilized with 0.25% (v/v) Triton X-100 at room temperature for 40 minutes. Permeabilized
cells were washed 3x with PBS (5 min each), and blocked with 1% (w/v) bovine serum albumin
(BSA) in PBS for 1.5 hrs. Cells were then washed 3x with PBS (5 min each) and incubated with
primary antibody. Primary antibodies for vWF staining and PECAM-1 were Anti-von Willebrand
Factor IgG antibody produced in rabbit (Sigma-Aldrich, St. Louis, MO), and Anti-PECAM-1 IgG1
antibody produced in mouse (EMD Millipore, Darmstadt, Germany), respectively, and each was
diluted 1:50 in 1% BSA/PBS. Cells were incubated with primary antibodies at 4 ºC overnight.
After overnight incubation, primary antibody solutions were removed and cells were washed 3x
with PBS (5 min each), and the secondary antibodies were applied to cells and incubated at room
temperature on a shaker for 2 hours. Fluorescein Isothyocyanate (FITC) conjugated secondary
antibodies for vWF and PECAM-1 were Anti-rabbit IgG-FITC and Anti-Mouse IgG-FITC,
respectively, and were diluted 1:50 in 1% BSA/PBS. All work with secondary antibodies was
performed in the dark, to prevent FITC photobleaching. Cultures without incubation in primary
antibodies were incubated in secondary antibodies as a negative control. After 2 hours incubation,
cells were washed 3x with PBS (5 min each), and DAPI solution (1 μg/ml PBS) was applied to
stain nuclei for 5 minutes. DAPI was removed, and cells were washed 3x with PBS, and imaged
for vWF and PECAM-1 expression. vWF and PECAM-1 expression of EPs was compared to a
negative control of undifferentiated MSCs.
6.4.3 Coating Microcapsules in Collagen and EPs
To facilitate accessory cell attachment to the microcapsule exterior, microcapsules were
coated with an adsorbed layer of collagen Type 1 prior to external cell attachment using an
established protocol [7]. All reagents used were sterile and used at 4 ºC unless otherwise noted.
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Microcapsules were washed with dilute chitosan solution (0.06% (w/v) chitosan in 0.04% (v/v)
acetic acid) for 2 min, washed briefly with 0.9% (w/v) saline, and washed with dilute collagen
solution (0.2 mg collagen Type 1/ml in 1 mM acetic acid) for 2 min. Collagen solution was
removed, and coated capsules were washed briefly with 0.9% saline, and equilibrated with
L.DMEM for 30 minutes. During coated capsule incubation, accessory cells (MSCs and EPs) were
trypsinized, centrifuged, and seeded at a density of 5x105 cells per ml of settled microcapsules in
37 ºC medium. The cell suspension was incubated with the microcapsules at 37 ºC for 60 minutes,
with gentle resuspension every 10 minutes, to facilitate attachment of accessory cells to coated
microcapsules. After incubation, seeded capsules were transferred to culture dishes for 48 hours
in standard media at 37 ºC prior to capsule fusion.

Fig 6.1: Attachment of MSCs to collagen coated microcapsules. After OP encapsulation, microcapsules were
washed in chitosan, coated in collagen Type 1 (Col-I), and accessory cells were allowed to attach to adsorbed ColI fibers on microcapsule exterior.

6.4.4 Subcutaneous Implant of Fused Microcapsule Constructs
After 48 hours of static culture, the collagen and cell coated microcapsules were fused into
disc constructs (6 x 5 mm, diameter x height) using a similar method as Chapter 5, section 5.4.1,
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for in vivo evaluation of vascularization (summed in fig 6.3). Briefly, cultured microcapsules were
rinsed with PBS, reloaded in dilute polyanion solution, and transferred to a mold with a porous
base. After draining excess polyanion solution, the mold was perfused with dilute chitosan. After
draining the chitosan solution, the fused constructs were perfused with dilute polyanion and
subsequently washed with 0.9% saline. The disc constructs were carefully removed from the mold,
and placed in Hanks Balanced Salt Solution (HBSS) and stored at 4 ºC to await subcutaneous
implantation. All solutions were sterile, and used at 4 ºC to protect cell metabolism.
Doppler US analysis of blood flow and analysis of tissue regeneration in the fused
constructs was evaluated by implanting the fused constructs into Sprague Dawley (SD) rats
(summed in fig 6.2). In this study, female rats (Charles River Laboratories, Wilmington, MA) aged
6-8 weeks, between 175-200 grams were used for all in vivo studies. All fused constructs contained
microcapsules with HAP microgranules, Aceullar fused constructs were implanted without cells,
OP fused constructs contained encapsulated OPs in the microcapsules, OP+MSC fused constructs
contained OP microcapsules with MSCs attached to the microcapsule exterior, and OP+EP fused
constructs contained EPs attached to the microcapsule exterior. A total of nine rats were used for
this study, each receiving one fused construct from each condition (four implants per rat), and the
implants were placed subcutaneously between the dorsal muscle and skin. Groups of four or five
rats were initially housed together following surgery. Prior to surgery, Buprenorphine SR Lab was
administered as an analgesic at a dose of 0.4 mg/kg. Rats were anesthetized with 1-3% isoflurane,
and maintained on this for the duration of the surgery. Briefly, a 4 cm x 4 cm patch of dorsal skin
was shaved, sterilized, and four 1 cm long incisions with 1.5 cm of undermining (for subcutaneous
pocket formation) were made in the sterilized dorsal area: care was taken so that incisions were at
least 1 cm away from each other to insure separation of all implants. Each rat received 2

85

subcutaneous pockets on the left and right dorsal side of each rat, above the external oblique
muscle. After placing the fused constructs in the incisions, the incisions were closed with 3-0
monofilament nylon sutures. Care was taken so that the implants did not lie directly under the
sutures. Blood flow through the implants was analyzed in vivo via Doppler US at 1, 2 and 4 weeks
post-surgery. Implants were excised at 1, 2 and 4 weeks for gross macroscopic analysis and
histology.

Fig. 6.2: Implanting fused constructs in rat subcutaneous pockets. Fused constructs that were Acellular, or
contained OP, OP+EP or OP+MSC were implanted and imaged via Doppler Ultrasound (US) after 1, 2 and 4 weeks
post-surgery. Doppler US produces gray scale images of implant (outlined in yellow dashes), with overlaid blood
flow in red and blue (color depends on direction of flow).

6.4.5 Doppler Ultrasound Analysis of Blood Flow through Fused Constructs
At 1, 2 and 4 weeks post-surgery, blood flow through implanted fused constructs was
analyzed via Doppler US in accordance with established protocols, and at least 3 rats were
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analyzed per timepoint [112, 113]. Rats were anesthetized with 1-3% isoflurane, and the hair on
the skin above implanted constructs was removed via depilatory cream (Nair ®). Briefly, a thick
layer of depilatory cream was applied to the hair, let sit for 1 minute, and removed with gauze and
DI water. After hair was removed, the affected skin was washed thoroughly with DI water and
cleaned gently with baby wipes (Charmin ®) to thoroughly remove residual cream. Rats were
placed on a precision xyz-stage, and ophthalmic ointment was applied to the eyes of the rats.
Ultrasound hydrogel was applied to the skin around the implants, and a focused US transducer
probe (32 MHz frequency) connected to a Vevo 2100 US system (Siemens, Munich) was applied
to acquire photoacoustic (PA) images of the implant (B-mode) and blood flow through the
implants (photoacoustic/Doppler mode, 35 dB gain). The PA images were overlaid on the B-mode
images to identify the location of blood vessels relative to implant material. The transducer probe
was fitted to a holder and lowered to contact US hydrogel on the implants, and the precision stage
was used to move the probe along the surface of the skin above the implant. Images of B-mode
implant overlaid with PA blood flow were captured every 0.5 mm along the surface of the implant
(moving from head to tail). US data was used to calculate an average vascular area fraction (VAF)
for each implant by counting the number of colored pixels in an implant region of interest (ROI),
and dividing this by the number of pixels in the implant ROI, using ImageJ software (NIH,
Bethesda).
6.4.6 Histological Analysis of Implants: Hematoxylin and Eosin, and Masson’s Trichrome
After 1, 2 and 4 weeks, at least 2 rats were euthanized via CO2 inhalation, and implants
were harvested for cell density and tissue ECM deposition via histology. Implants were removed
and immediately fixed and stored in neutral buffered formalin (NBF, 10%). After extensive washes
with first PBS and then DI water, the specimens were decalcified in a solution of 12% (v/v) HCl,
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0.07% (w/v) EDTA, 0.014% (w/v) sodium tartrate, and 0.8% (w/v) sodium and potassium tartrate
for 24 hours [114]. After 24 hours, the decalcified tissue was immediately removed and washed in
running room-temperature tap water for 30 minutes, then equilibrated with 3x changes of DI water
(30 minutes each). Washed tissue was dehydrated through a graded ethanol series (70% overnight,
90% (2x) for 2 hrs, 95% (2x) 2 hrs, 100% (2x) for 2 hrs), cleared in xylene under vacuum (3x
changes, 30 minutes each), and incubated with paraffin (2x 1 hr each). The implants were finally
incubated in a third change of paraffin overnight. Paraffin embedded implants were sectioned
parallel to the muscle/skin sides of the implant, to obtain 7 μm thick horizontal sections beginning
at 1 mm into the implant from the muscle side, to examine tissue and ECM towards the center of
the implant. Sections were deparaffinized in xylene (2x, 5 min each), rehydrated through a graded
ethanol series (100% to 40%), and incubated in DI water (3x, 5 min each).
For routine hematoxylin and eosin (H&E) staining, nuclei on sections were stained with
Weigert’s iron hematoxylin (10 minutes), washed in warm running tap water (5 minutes), blued in
0.2% ammonia water (10 minutes), washed in warm running tap water (5 minutes), and
equilibrated with DI water (2x changes, 5 min each). Sections were then rinsed in 70% (v/v)
ethanol, and counterstained in Eosin Y working solution (2 minutes). Sections were then
dehydrated through an ethanol gradient (85%, 95%, 100%, 2x changes of each for 2 minutes each),
equilibrated with xylene (2x changes, 3 minutes each), and finally cover slipped in xylene-based
medium (Permount ®). To determine blood vessel density of each implant (including capillaries
with D < 30 μm), blood vessels were counted in H&E stained sections. For this study, blood vessels
were defined as luminal structures containing erythrocytes. Data will be reported as vessels/mm2
For Masson’s Trichrome staining, rehydrated sections were incubated in mordant (Bouin’s
solution) for 24 hours prior to staining, and staining was conducted using reagents from a kit
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(Sigma-Aldrich, St. Louis, MO). Sections were washed in running tap water (10 min), equilibrated
with DI water (2x changes, 5 min each), and stained in Mayer’s hematoxylin (8 min). Stained
sections were blued in Scott’s tap water (10 min), washed in running tap water (5 min) and washed
in DI water (2x 5 min each). Sections were then stained in Biebrich Scarlet-Acid Fuschin (5 min),
rinsed in DI water (5 min), stained in working phosphotungstic/phosphomolybdic acid solution (5
min), and placed in aniline blue solution (5 min). After staining, sections were differentiated in 1%
(v/v) acetic acid, and dehydrated through an ethanol gradient, equilibrated with xylene and cover
slipped in a similar protocol to H&E staining. Stained sections were observed for cell infiltration
and tissue/ECM deposition in the microcapsules and between microcapsules (intercapsule space),
at the edges and centers of the implants. Implant edges were defined as the regions 1 mm from the
periphery of the implant-tissue interface towards the center, and the center of the implant was
defined as a 2 mm diameter region equidistant from the implant edges.
6.4.7 Histological Analysis of Undecalcified Implants: Alizarin Red Staining.
After harvesting implants, some implants were left undecalcified, and embedded in methylmethacrylate (MMA) blocks for hard tissue sectioning, to analyze mineral deposition between
weeks 1 and 4. Because the sectioning process is expensive (sectioning was conducted at Rush
Medical School, Chicago, IL), only Acellular, OP+EP and OP+MSC implants from week 1 and 4
were analyzed. After fixation, implants were washed, dehydrated in 70%, 90%, 95%, and finally
100% ethanol (2 days each), cleared in xylene (1 day), and incubated in a series of MMA solutions,
each for 48 hours at 4 ºC: 1) a 17:3 solution of MMA:diphthalate (DP), 2) a 17:3 solution of
MMA:DP with 1% (w/v) benzoyl peroxide, 3) a two changes of a 17:3 MMA:DP solution with
2.5% (w/v) benzoyl peroxide. Air bubbles were removed from the implants in 2.5% benzoyl
peroxide 17:3 MMA:DP solution by placing under vacuum for 24 hours, and releasing the vacuum
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every 30 minutes. The MMA was cured around the implants by heating the vessels in a water bath
at 42 ºC overnight. The resulting MMA blocks were sectioned at Rush Medical Center (Chicago,
IL) to create 8 μm sections.
After sectioning, MMA embedded sections were deplasticized in acetone (3 changes, 10
min each), and rehydrated in an increasing ethanol gradient (95%, 80%, 70%, 50%, 40%, 25%, 2
changes for 2 min each). Sections were finally hydrated in 3x changes of DI H2O (5 min each).
Alizarin Red S working solution (2% (w/v) Alizarin Red S in DI H2O, pH 4.2 adjusted with
ammonium hydroxide) was applied to the slides, and slides were observed under a microscope for
red staining of mineral deposits (~ 5 min). After staining, excess Alizarin solution was removed,
slides were blotted, and dehydrated in acetone for 20 dips. Slides were subsequently dehydrated
in 50:50 acetone:xylene solution (20 dips), dehydrated in 3x changes of xylene (3 min each), and
finally mounted with a coverslip. Mineralization on sections was visualized via bright field
microscopy.
6.4.8 Statistical Analysis
Statistical analysis was carried out using GraphPad Prism software. All statistical
comparisons were made by performing a two-way analysis of variance (ANOVA), followed by
Bonferroni’s multiple comparison tests to evaluate significance between two data sets at a time. P
values less than 0.05 were considered statistically significant. All data is reported as the mean +
standard deviation.
6.5 Results:
6.5.1 Endothelial Progenitors Display Endothelial Markers
Induction of MSCs in endothelial induction medium produced Endothelial Progenitors
(EPs) that displayed in vitro angiogenic activity and membrane markers characteristic of
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endothelial cells. The in vitro angiogenic activity was assessed via capillary-like network
formation on Matrigel. EPs seeded in Matrigel in the absence of VEGF quickly formed a capillary
network after 12 hours in culture (fig. 6.3a), while un-induced MSCs retained aggregate/spherical
morphology with some lamellipodic spreading on the Matrigel. Undifferentiated MSCs did
construct capillary networks when seeded on Matrigel in the presence of VEGF (50 ng/ml, fig.
6.3a). The ability to form capillaries on a semi-solid medium is a hallmark of endothelial cells
[110, 115]. Additionally, EPs presented cell-membrane markers vWF and PECAM-1 (Fig 6.3b),
while these membrane markers were absent from un-induced MSCs. PECAM-1 and vWF are both
characteristic membrane markers of endothelial cells: vWF allows endothelial cells to mediate the
progression of thrombus formation by binding to platelets, and PECAM-1 facilitates cell-cell
adhesion in endothelial cells that promotes tube formation [116, 117]. The results of tube formation
and vWF/PECAM-1 expression presented here agree well with reports from the literature of MSC
differentiation to an endothelial-like lineage [110, 111, 118]. Additionally, these results are similar
to those obtained for EPs that promoted vascularization and bone regeneration when implanted in
vivo in published studies [119]. This brief study confirms that MSCs harvested for this study can
be differentiated to an endothelial-like lineage (EPs), and the next series of studies will analyze
how the addition of these EPs can enhance the vascularization of fused microcapsule constructs in
vivo.
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Fig. 6.3 Confirmation of MSC differentiation to Endothelial Progenitor (EPs). (a) EPs formed a tube-like
network across the surface of Matrigel after 12 hours in culture, without the aid of exogenous VEGF supplemented
in medium. EPs were compared to MSCs as a negative control. (b) EPs expressed common endothelial markers
von Willebrand’s Factor (vWF) and Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1).

6.5.2 EPs Attachment to Collagen Coated Microcapsules
Differentiation of MSCs to OPs during three weeks of culture prior to encapsulation was
confirmed via Alizarin red staining of representative cultures that showed reddish/orange mineral
deposits across the cell monolayer (fig 6.4). After OP encapsulation, coating of microcapsules with
collagen and attachment of EPs or MSCs, microcapsules were cultured for 48 hours prior to fused
construct fabrication and implantation. Labelling of representative OPs, MSCs and EPs with
fluorescent cell tracking probes (Cell Tracker Red for OP, Cell Tracker Green for MSCs and EPs)
to show how accessory cells attach to the microcapsule exterior (fig 6.5). Accessory cells attach
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as aggregates (or attach individually and form aggregates) during the 1 hour incubation after
collagen coating of microcapsules, and stay in partial aggregate form for 48 hours of culture, until
microcapsules are fused for implantation (fig 6.5a, b) . SEM analysis of microcapsules confirmed
that accessory cells were attached to microcapsules as aggregates (fig 6.5c, d): there was no
difference in the attachment of MSCs or EPs to collagen coated microcapsules. Once the
microcapsules are fused, these exterior cells will be localized to the pore space of the fused
construct.

Fig. 6.4 Staining of mineral-containing nodules in OPs prior to encapsulation. MSCs were osteoinduced for 3
weeks, then stained with Alizarin Red S to identify mineral (red/orange regions) and confirm osteoinduction.
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Fig. 6.5: Accessory cell attachment to microcapsule exterior. (a) Phase contrast image of EPs attached to
microcapsule exterior. (b) fluorescent image of (a), showing labelled encapsulated OPs (red) and EPs (green).
Yellow fluorescence occurs form the overlap of the red and green. (c) SEM image of microcapsule with cell
aggregate attached and partially spread on exterior. (d) higher magnification of (c).

6.5.3 Ultrasound Analysis of Fused Construct Vascularization
Blood flow in and around implanted fused constructs was assessed by Doppler US at 1, 2
and 4 weeks post-surgery. US images show after 1 week post-surgery, the constructs have lost
their disk-shape, and were likely partially flattened from rat grooming, rat bedding, and possibly
from application of the US probe, but further distortion of implant size and shape did not appear
to occur over the four weeks post-surgery (fig 6.7). Moreover, US images showed the presence of
blood vessels 1 week post-surgery primarily around the periphery (between the implant and skin)
of the implants, and the vessels appear to be travelling along the surface of the implants in parallel
with the skin/muscle surface (fig. 6.7a, d, g, and j). In the case of the OP+EP and OP+MSC
implants, vessels were observed running under the implant surface, closer to the implant center
(fig 6.7g and j, respectively). Few vessels were detected with the US probe around or within the
implants of any condition after 2 weeks post-surgery, and only some small diameter vessels were
observed near the implant surface in the OP+EP and OP+MSC conditions (fig 6.7h and k,
respectively). By week 4 post-surgery, acellular implants still showed very little vascularization
(fig 6.7c); however, all implants containing cells (OP, OP+EP, OP+MSC) showed blood vessels
at the implant border and near the implant center (fig 6.7f, i, l). Specifically, in the case of OP+EP
and OP+MSC implants, more vessels appear to have penetrated the interior of the implants, again
running parallel with the skin and muscle. US results indicate that after 4 weeks post-surgery,
implants with accessory cells attached to the microcapsule exterior have enhanced vascularization,
particularly within the construct, and not just at the implant border.
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Fig. 6.6: Macroscopic images of implants excised at 4 weeks post-surgery. (a) Acellular, (b) OP, (c) OP+MSC,
(d) OP+MSC. All excised implants showed some evidence of larger vessels along the surface of the impalnts.
Implants were excised with skin (under implant) attached.
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Fig. 6.7: Representative Ultrasound (US) images for weeks 1, 2 and 4 post-surgery. (a-c) Acellular, (d-f) OP,
(g-i) OP+EP, and (j-l) OP+MSC fused constructs. Red and blue denote blood flow, scaffold and nearby rat tissue
appear gray-white.

A quantitative analysis of the US data shows the temporal change in vascularization for
each implant (fig. 6.8). At 1 week post-surgery, all of the implant conditions have similar average
VAFs from 0.034 to 0.043 of total implant area. Interestingly, the average VAF appears to decrease
for all conditions after 2 weeks post-surgery; additionally, there was no statistical difference
between the conditions during week 2. The quantitative analysis shows possible evidence of
vascular regression between weeks 1 and 2, at least concerning vessels larger than the lower
resolution (30 μm) of the Visual Sonics 2100. After 4 weeks post-surgery, the average VAF for
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the OP+EP implants increased significantly above week 2 values for all conditions, showing
enhanced vascularization of implanted constructs between weeks 2 and 4. Specifically, the fused
constructs with EP had a significantly higher average VAF (0.087 + 0.0511) than either OP (0.019
+ 0.014) and acellular (0.020 + 0.019) constructs at 4 weeks post-surgery. The addition of
accessory cells (EPs and MSCs) to the exterior of microcapsules in fused constructs appears to
stabilize (prevent from regressing) the blood vessel network after 4 weeks post-surgery: the
average VAF at week 4 for the OP+MSC implants was not statistically different than week 1, and
was not lower. Interestingly, there was no statistical difference in average VAF between OP+EP
and OP+MSC implants at week 4. The average VAF of the acellular fused constructs at week 4
were also not statistically lower than week 1. The US data suggests that the addition of EPs and
MSCs to the exterior of microcapsules stabilizes the in vivo vascularization of fused microcapsule
constructs, and may even enhance the vascularization after 4 weeks in the case of implants with
EPs. Results from previous studies suggest that improving vascularization of implants leads to
faster bone regeneration in vivo.
There are some differences when comparing our results to similar studies utilizing US in
the literature. A β-Tricalcium phosphate scaffold (β-TCP) seeded with collagen and HUVECs
implanted in immunodeficient mice showed increasing VAF between weeks 1 and 2 (the study
ended at week 2), instead of the decrease between weeks 1 and 2 observed here [112]. Differences
in the scaffold system could explain the differences in vascularization: the β-TCP scaffolds were
donut shaped cylinders (8 mm x 5 mm diameter x height) that contained a 3 mm diameter central
pore. This large pore would rapidly fill with infiltrating cells, including endothelial cells that could
establish a vascular network within the β-TCP scaffold early after implantation. Additionally, the
study used a defined endothelial line (HUVECs), instead of the EPs used for the modular fused
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constructs. EPs were chosen for this study due to their practical translatability to the clinic: MSCs
are easily harvested in the clinic, and the differentiation materials are relatively inexpensive.
Moreover, the β-TCP donut scaffold is likely suitable for regenerating large bone segments such
as long bones, but the geometry is less suitable for regenerating bone in defects of complex
geometry, or where minimally invasive surgical techniques are sought. The modular system
designed here is meant to apply in different bone regeneration scenarios requiring bone
regeneration of complex geometry, varying size, and possibly utilizing minimally invasive surgical
techniques for implantation.

Fig. 6.8: Quantification of Vascular Area Fraction from US data for weeks 1, 2 and 4 post-surgery. P<0.05
(N=4) Relative to Acellular at week 2, # P<0.05 (N=4) Relative to OP at week 4, ^ P<0.05 (N=4) Relative to all
conditions week 2, $ P<0.05 (N=4) Relative to Acellular at week 4, @ P<0.05 (N=4) No statistical difference
between groups.

It is somewhat surprising that there was no statistical difference in vascularization between
the OP+EP and OP+MSC fused construct implants at 4 weeks post-surgery, but reports in the
literature have demonstrated that undifferentiated MSCs enhance scaffold vascularization in vivo,
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without the addition of other exogenous factors [120, 121]. Several possible mechanisms for this
have been proposed, including 1) MSC secretion of MMPs that enhance native endothelial cell
migration through an implant [120], 2) paracrine signaling via extracellular vesicles containing
proangiogenic growth factors (VEGF, TGFB1, IL-8) [122], and 3) supporting blood vessel
maturation in a pericyte-like function [121, 123]. The inherent porosity of the fused constructs
makes it unlikely that MMP secretion would increase native endothelial cell migration through the
implant, so the accessory cells likely promote vascularization via mechanisms 2 and 3.
Unfortunately, it is impossible with the current data to determine specifically how the accessory
cells have enhanced fused construct vascularization in the OP+EP and OP+MSC fused constructs.
For instance, the cells were not labelled prior to implant, and it is not possible to distinguish
implanted EPs from native endothelial cells (or implanted MSCs from native pericytes) in the
implant vasculature.
6.5.4 Histological Evaluation of Fused Constructs
Implants were excised after 1 and 4 weeks post-surgery, and decalcified to aid routine H&E
processing. Empty, round voids observed in the histology sections are voids from the
decalcification of the spherical HAP microgranules (fig 6.9). H&E staining and assessment of the
implant edges of horizontal sections indicates that fused constructs containing cells were quickly
infiltrated with native rat tissue cells. After 1 week post-surgery, sparse connective tissue cells are
observed infiltrating between the microcapsules at the edge of the Acellular fused construct, and
growing along the exterior membrane of the microcapsules (fig 6.9a). Moreover, hematoxylinstained nuclei can be seen in the microcapsules near the edge in the Acellular construct, indicating
that native cells invaded the microcapsule interior in this fused implant condition. In comparison,
all fused constructs containing cells showed dense tracks of cells and native tissue leading into the
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center of the implant between the microcapsules at the implant edge after 1 week (fig 6.9b-d). In
all conditions at week 1, the infiltrating cells mostly appear elongated with round nuclei, consistent
with connective tissue/fibroblast cells. Notably, some cells with perfectly round, larger nuclei are
present between the microcapsules at the implant edges in the cell-containing implants, and it’s
possible these could be plasma cells commonly associated connective tissue (fig 6.9b-d). In all
conditions 1 week post-surgery, evidence of the microcapsule membrane (stained dark red from
eosin staining chitosan) is clearly present, indicating minimal degradation.
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Fig. 6.9: H&E histological assessment of implant edges. (a, e) Acellular implants week 1-4, (b-f) OP implants
weeks 1-4, (c-g) OP+MSC implants week 1-4, (d-h) OP+EP implants weeks 1-4. Black arrows point to implanttissue interface. White spherical voids were filled with HAP microgranules prior to implant decalcification.

After 4 weeks post-surgery, more cells have infiltrated the edges of the Acellular implants,
and the connective tissue growing between the microcapsules appears substantially thicker
compared with week 1 (fig 6.9a, e). Additionally, the red microcapsule membranes are still clearly
evident 4 weeks post-surgery, indicating minimal degradation of the microcapsule material, even
after 4 weeks post-surgery and exposure to degrading enzymes (lysozyme, etc…) associated with
the in vivo environment (fig 6.9e). In contrast, the fused constructs containing cells appeared to
have similarly dense connective tissue in the intercapsule space at week 4, compared with week 1
(fig 6.9f-h). Interestingly, very little evidence of the microcapsule membrane was found in the OP,
OP+MSC or OP+EP microcapsules at the edge of the implants at week 4, indicating significant
degradation of the membrane occurred between weeks 1-4. Moreover, connective tissue can be
observed growing and infiltrating between the HAP microgranules formerly encapsulated by the
microcapsule membranes, indicating either native cell infiltration inside the microcapsules,
enhanced proliferation of OPs inside the microcapsules, or a mix of both mechanisms. No
difference in cell infiltration or density was observed between OP and OP+MSC/OP+EP implants
at weeks 1 or 4 post-surgery. Histological assessment of implant edges shows that OP, OP+MSC
and OP+EP implants facilitated quick native cell and connective tissue infiltration early after 1
week post-surgery, and that cell density was maintained after 4 weeks post-surgery. Additionally,
microcapsules near the edge of the OP, OP+MSC and OP+EP implants contained significantly
more cells (either native infiltrating cells or proliferating implanted cells) at week 4. Finally, it
appears that the microcapsule membrane degraded significantly between weeks 1-4 post-surgery
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in the OP, OP+MSC and OP+EP implants, possibly due to the greater cell infiltration and blood
flow (with degrading enzymes) compared with Acellular implants.
H&E assessment of the center of the implants shows a trend similar to the implant edges.
At week 1, the Acellular implant had very few cells infiltrated to the center of the implant: only a
few sparse nuclei could be observed in the intercapsule space, and most of the intercapsule space
was acellular and empty (fig 6.10a). The cells in the center of the Acellular implant have rounded
nuclei with minimal cytoplasm and a spherical phenotype. Moreover, very few capsules in the
center contained nuclei, indicating minimal invasion into the microcapsules by infiltrating native
cells. In contrast, the OP, OP+MSC and OP+EP fused constructs all contained significant
infiltrating cells at their centers, early 1 week post-surgery (fig 6.10b-d). Similar to the implant
edges, the infiltrating cells in the OP, OP+MSC and OP+EP implants appeared to have an
elongated, connective tissue fibroblast phenotype. Additionally, most of the capsules in the center
of OP, OP+MSC and OP+EP implants contained cells, though it appears more cells were present
in the microcapsules at the implant edges at week 1 post surgery (fig 6.10b-d vs. fig 6.9b-d). The
higher diffusion of nutrients near the microcapsules at the edge of the implant, or the greater
probability of cell invasion, likely contributed to the higher cell density in the microcapsules near
the implant edge. Similar to the trend observed at the edges of the implant, more native connective
tissue cells have quickly infiltrated to the centers of the OP, OP+MSC, and OP+EP implants,
compared to Acellular implants at 1 week post-surgery.
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Fig. 6.10: H&E histological assessment of implant center. (a, e) Acellular implants week 1-4, (b-f) OP implants
weeks 1-4, (c-g) OP+MSC implants week 1-4, (d-h) OP+EP implants weeks 1-4. White spherical voids were filled
with HAP microgranules prior to implant decalcification.

After 4 weeks post-surgery, more connective tissue cells have infiltrated the intercapsule
space in the center of the Acellular implant, so minimal empty space is observed compared to week
1 (fig 6.10e). There are still few microcapsules in the center of the Acellular implant that contain
nuclei at week 4, indicating minimal cell invasion into the microcapsules. In fact, the microcapsule
membranes are clearly intact in the center of the Acellular construct at week 4, showing minimal
(if any) degradation. The connective tissue infiltration was significantly more dense in the center
of OP, OP+MSC and OP+EP implants than the Acellular condition (fig 6.10f-h). Moreover,
microcapsules in the center of the OP, OP+MSC and OP+EP constructs contain significantly more
cells at week 4 compared to week 1 (fig 6.10f-h). Interestingly, more evidence of the microcapsule
membranes (darker red staining than surrounding cytoplasm) is present in the center of the
microcapsule construct than the edges after 4 weeks post-surgery. Results demonstrate that cells
quickly proliferated in the center of the fused OP, OP+MSC, and OP+EP constructs, and the
cellular density of microcapsules in the center increased between weeks 1 and 4. Moreover, the
microcapsule membranes appeared less degraded in the center of the fused constructs than at the
edges after 4 weeks post-surgery, likely due to greater exposure to lysozyme in the circulating
blood at the implant edges.
It is notable that a significant immune/inflammatory response is not present in the H&E
stained sections. The densely-packed neutrophils of an inflammatory response are not obviously
present in weeks 1 or 4 in vivo when reviewing the H&E stained sections. Additionally, the
presence of multi-nucleated foreign body cells or basophils was not obvious either. Previous
studies examining the in vivo host response to chitosan materials describe an early neutrophil
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recruitment, but without neutrophil activation [124, 125]. However, the chitosan used for
implanted microcapsules was 95% de-acetylated, which would illicit a significantly reduced
inflammatory response [126]. Furthermore, C4S has demonstrated anti-inflammatory properties in
vivo. It is possible that the OPs, which were of MSC origin, suppressed an inflammatory immune
response to the fused constructs. Research indicates that MSCs have a wide array of
immunomodulatory properties, including the secretion of the multifunctional tumor necrosis
factor-α (TNF-α), stimulated gene/protein 6 (TSG-6), and the IL-1 receptor antagonist [127]. The
MSCs may have retained some of these properties during their differentiation to OPs or EP, and
actively suppressed an immune response. The combination of microcapsule materials used
(deacetylated chitosan and C4S), and MSC-derived cell types, may have suppressed a host immune
response to the fused microcapsule implants.
It’s clear that fused constructs with exogenous cells significantly enhance cell density of
the implanted constructs after 4 weeks in vivo. The increased cell density could be the result of a
few different mechanisms: 1) exogenous cells in the fused constructs could experience increased
proliferation from the nutrients and growth factor milieu available in vivo, and/or 2) exogenous
OPs, MSCs, and EPs promote homing of native cells to the implant area through paracrine activity.
It is possible that some of the transplanted cells proliferated in the implant during weeks 1-4, and
several studies have shown that implanted cells contribute to tissue regeneration and anastomosis
with host tissue. A specific study that was a partial inspiration for this work (and discussed indepth in the relevant background, section 2.5) demonstrated that the exogenous EPs implanted in
a PCL/HAP scaffold anastomosed with the host vasculature in the defect [50]. Indeed, the
encapsulated OPs in the microcapsule system described here are physically constrained by the
microcapsule membranes, and will participate in tissue regeneration by depositing matrix and
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proliferating within the microcapsule space. It is possible that the membranes of some
microcapsules may have become compromised after surgery, but the histological assessment
shows that most of the membranes appear in tact at week 1.
Some prior research reports indicate that implanted cells don’t participate directly in tissue
regeneration in every system, and often migrate away from the implant following hypoxic and
chemotactic cues from the surrounding tissue [128]. In fact, a detailed study examining how
allogenic MSCs implanted in a ceramic bioscaffold in a mouse model contributed to bone
regeneration demonstrated that these MSCs migrated out of the subcutaneous implants into the
circulatory flow [129]. Interestingly, the exogenous MSCs did significantly improve recruitment
of endogenous cells to the implanted bioscaffold, likely by the release of homing factors as they
migrated out of the implant. The paracrine signaling by exosomes containing proangiogenic
growth factors released from MSCs has been discussed in the previous section. The MSC-secreted
exosomes also contain some chemotactic factors that could induce migration of native cells to the
implant area: some chemotactic cues released by MSCs include stromal cell-derived factor 1 (SDF1) [130], hepatocyte growth factor (HGF) [131], VEGF [132], and interleukin 8 (IL-8) [133]. Of
specific interest in this study, MSCs have been shown to induce the migration of fibroblasts via a
chemotactic trail [131], and this may explain the increase in connective tissue for OP, OP+MSC
and OP+EP implants, compared with Acellular implants. The OPs are derived from MSCs for this
study, and studies demonstrate that MSCs continue to secrete GFs and exosomes during
osteogenesis [134]. However, the secretome of MSCs undergoing osteogenesis hasn’t been
completely characterized at the date of this manuscript, so claims of OP exosome-mediated
migration are very limited. It’s possible that the encapsulated OPs are secreting exosomes with
pro-migratory cues, promoting the migration of native cells into the fused constructs. Results
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combined with this native cell migration hypothesis demonstrate the utility of adding cells to the
fused construct implants to promote rapid cellularization of fused constructs and tissue
regeneration.
6.5.5 Blood Vessel Density assessed from Implant Histology
Due to the inability of the ultrasound system to identify blood vessels with diameters less
than 30 μm, blood vessels observed in the histological sections were quantified for all implant
conditions (fig. 6.11). Representative images showing blood vessels in H&E stained sections are
shown in fig. 6.11 (a-d): contrast and brightness are adjusted to better show erythrocytes in vessel
lumens. Quantification of the blood vessel density shows a trend slightly different than the VAF
determined from the US analysis of larger blood vessels. The vessel density significantly increased
for both OP+MSC (1.83+0.07 to 8.06+0.36 vessels/mm2) and OP+EP implants (1.48+0.07 to
8.53+0.25 vessels/mm2) between weeks 1-3, respectively (fig. 6.11e). In contrast, the vessel
density of Acellular and OP implants stayed relatively the same between weeks 1-3. Interestingly,
the vessel density of the OP+MSC and OP+EP implants increased between weeks 1 and 2, contrary
to the US data discussed previously. The blood vessel density calculation performed in this section
captured the smaller capillaries (D < 30 μm) present in the vessels at week 2 that the US probe
missed, due to the resolution limit of the probe. During week 4 of implant period, there was no
statistical difference between the OP+MSC and OP+EP implant vessel density, but both were
significantly higher than the Acellular and OP implants at week 4. Interestingly, the vessel density
of OP+EP implants was lower than OP+MSC and OP implants at week 1 (1.48+0.07 vs. 1.83+0.07
and 2.09+0.11 vessels/mm2, respectively); however, this could be a feature of the low sample size
of tissue sections (n=3) counted for this assessment.
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Fig. 6.11: Blood vessel density quantification. Representative histological images showing blood vessels (black
arrows) for (a) Acellular, (b) OP, (c) OP+MSC, and (d) OP+EP implants after 4 weeks in vivo. (e) Blood vessel
density quantification for all implants at 1, 2 and 4 weeks (n=3). * (P < 0.05) significant from previous time point.
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# (P < 0.05) significant from OP at that time point. $ (P < 0.05) significant from Acellular at that timepoint. ^ (P <
0.05) significant from all other conditions at that time point.

The blood vessel density quantification exhibits a different trend for the VAF calculations
from US assessment. It appears that some larger vessels (present during the first week of in vivo
implantation) may have remodeled into smaller capillaries via vessel intussusception.
Intussusception involves the splitting of an existing vessel in two: the vessel is split along its long
axis, to create two vessels with a smaller diameter than the original [135]. It has been demonstrated
that vessel intussusception occurs in low-VEGF environments in both chick embryo
vascularization models [136] and tumor vasculatures undergoing anti-angiogenic therapy [137].
It’s entirely likely that a low VEGF environment was present in the implants during the first couple
of weeks after implantation in vivo, as the implanted cells would be the only possible source
capable of releasing VEGF. The MSCs/EPs contained in the implant may not have sustained
VEGF secretion and, even if they initially did secrete VEGF, these cells may have migrated out of
the implant during the initial weeks post-surgery. The current data suggests that some large vessels
present after week 1 post-surgery are remodeled into smaller capillaries by week 2 in the fused
microcapsules constructs, likely via low-VEGF intussusception. A more rigorous study is required
to determine the nature of the vascular remodeling, but this study currently demonstrates that
including EPs or MSCs in the fused construct implants significantly increases the implant vessel
density over the four weeks post-surgery, and this will likely lead to enhanced bone regeneration
in vivo.
6.5.6 Histological Evaluation of Matrix Deposition in Constructs
Tissue sections analyzed for histology were also analyzed for the presence of ECM
(collagen and GAG/protein) in and between microcapsules via Masson’s Trichrome staining.
Analysis of trichrome staining at the edges of all implants 1 week post-surgery (fig 6.12a-d)
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showed that cells infiltrating between the capsules deposited connective tissue collagen (light blue
staining from aniline blue dye). Similar to H&E analysis, nuclei were observed in the
microcapsules at the edges of the Acellular implants at week 1, indicating cell invasion into the
microcapsules (fig 6.12a). The tissue between the microcapsule edges at week 1 appeared to be
entirely collagen in Acellular, OP+MSC and OP+EP implants; however, significant red staining
was observed in the tissue around the edge microcapsules in the OP implant, indicating the
presence of GAGs and non-collagenous proteins (fig 6.12b). Like the H&E analysis, the
microcapsule membrane stains red under Masson’s Trichrome. Inside the microcapsules, the
OP+MSC and OP+EP constructs contained mostly collagen: in contrast, the OP microcapsules
contained significant GAGs/non-collagenous proteins. The specific red staining around the HAP
microgranules in the OP microcapsules is indicative of osteoid production, a high protein content
non-mineralized ECM deposited in the beginning of bone regeneration by osteoinduced
MSCs/osteoblasts [138]. Very little has changed in the matrix composition at the edges of the
Acellular implants after 4 weeks, and the matrix is still highly collagenous from connective tissue
infiltration (fig 6.12e). By week 4, the tissue surrounding OP microcapsules at the edge is
composed of collagen and protein/GAGs, indicated by the blue with interspersed red, and was
similar in composition to week 1 (fig 6.12f vs. 6.12b). In contrast, the edges of the OP+MSC and
OP+EP implants contained significantly more protein/GAG between the microcapsules after 4
weeks compared to week 1, and the tissue at week 4 was a mix of collagen/non-collagenous
proteins (fig 6.12g, h vs. fig 6.12c, d). Trichrome staining indicates that initially, loose collagen
and connective tissue is deposited between the microcapsules as native connective tissue
fibroblasts invade the implant at week 1, and this connective tissue is mostly present at week 4
with additional proteins and GAGs in the OP+MSC and OP+EP implants.
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Fig. 6.12: Masson’s Trichrome histological assessment of implant edges. (a, e) Acellular implants week
1-4, (b-f) OP implants weeks 1-4, (c-g) OP+MSC implants week 1-4, (d-h) OP+EP implants weeks 1-4.
Yellow arrow denotes implant-tissue interface. Nuclei = purple/fuchsia, collagen = blue, osteoid =
red/pink, microcapsule membrane = red. White spherical voids were filled with HAP microgranules
prior to implant decalcification.

Masson trichrome staining of the center of the implant shows a similar tissue composition
to the edges. Minimal tissue was observed in the intercapsule space in the center of Acellular
implants at week 1 (fig 6.13a), and no increase was observed by week 4 (fig 6.13e): matrix that
was present was faintly blue, indicating very loose collagen. The matrix deposited in the center of
OP constructs was mainly red at week 1, indicating non-collagenous protein/GAG containing
osteoid, surrounding some acellular islands of blue collagen (fig 6.13b). At 4 weeks post-surgery,
the acellular collagen islands in the center of the OP implants were stained significantly darker,
indicating more dense collagen deposition characteristic of woven bone regeneration (fig 6.13f)
[138]. Similar acellular islands of collagen were observed in the centers of OP+MSC and OP+EP
implants, and these also appeared more dense after 4 weeks post-surgery (fig 6.13c, d vs. fig 6.13g,
h). Trichrome staining of the central regions of all OP, OP+MSC and OP+EP implants indicates
early matrix deposition at week 1 (osteoid-like for OP, collagenous connective tissue for OP+MSC
and OP+EP), followed by better organization of deposited collagen to more dense, acellular islands
present at week 4. The analysis of deposited matrix shows the deposition of dense collagen, a
precursor to unmineralized woven bone, and the potential beginnings of intramembranous
ossification within the OP, OP+MSC and OP+EP fused constructs. Results indicate that an optimal
bone regeneration fused construct would contain, at a minimum, capsules filled with OPs.
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Fig. 6.13: Masson’s Trichrome histological assessment of implant center. (a, e) Acellular implants week 1-4,
(b-f) OP implants weeks 1-4, (c-g) OP+MSC implants week 1-4, (d-h) OP+EP implants weeks 1-4. Nuclei =
purple/fuchsia, collagen = blue, osteoid = red/pink, microcapsule membrane = red. dCT = Dense collagen tissue,
O= Osteoid. White spherical voids were filled with HAP microgranules prior to implant decalcification.

6.5.7 Alizarin Red Staining of Undecalcified Implants
Implants that were not decalcified were embedded in MMA blocks and sectioned for
mineral staining by Alizarin Red. Mineral deposition was relatively uniform over weeks 1-4
between Acellular, OP+EP and OP+MSC sections (fig. 6.14). The most intense staining appeared
in the centers of the HAP microgranules (dark red/black), and less-intense staining occurred at the
edges of the HAP microgranules. In the implants containing cells, there could be some celldeposited mineral around the HAP microgranules: indeed, there appears to be slightly more red
staining at week 4 in the OP+EP and OP+MSC sections, than in the Acellular sections at week 4.
Currently, more undecalcified implants must be sectioned, stained, and the images analyzed to
measure the stained areas and compare between groups. Additionally, the implants must be left in
vivo for a longer time (possibly 6 weeks or longer) to allow for sufficient mineral deposition to
occur from cells implanted with (or migrating into) the fused construct implants. The current
results show that the inclusion of OPs and EPs/MSCs may slightly enhance the mineral deposition
in the implants over a 4 week period in vivo.
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Fig. 6.14: Alizarin Red staining of undecalcified implant sections. (a, d) Acellular implants weeks 1-4, (b, e)
OP+EP implants weeks 1-4, (c, f) OP+MSC implants weeks 1-4. Calcium deposits = red. HAP microgranules =
dark red/black.

6.6 Summary and Discussion:
We have demonstrated that the addition of accessory cells (MSCs or EPs) to the
microcapsule exterior improves the vascularization of fused microcapsule constructs compared
with Acellular or OP constructs after a 4 week in vivo period. Doppler US data confirms that fused
constructs containing accessory cells had similar average VAFs at week 4 compared to week 1,
indicating that the accessory cells may have induced more native endothelial cells to migrate to
the implant over 4 weeks in vivo, preventing the regression of vessels in these implants. Moreover,
implants containing allogenic OPs, MSCs and/or EPs experienced significantly higher cell
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densities early after the first week of implant, possibly due to allogenic cell proliferation or
chemotactic recruitment of native cells. In particular, the OP+EP implants had a significantly
higher average VAF than OP and Acellular implants at week 4. Both OP+EP and OP+MSC
implants had higher blood vessel density than OP and Acellular implants after 4 weeks. This study
demonstrates that a fused construct containing microcapsules with encapsulated OPs and accessory
cells (MSC or EP) serves as a viable strategy to promote well-vascularized bone regeneration.
The specific type of tissue infiltrating and regenerating the scaffolds requires more
characterization. Currently, it is hypothesized the tissue is mainly composed of connective tissue
fibroblasts and mesenchymal cells, based on the cell morphology and that these cells would be the
first recruited in a subcutaneous implant model. Future immunohistochemical (IHC) studies should
be conducted to probe implants and tissue sections for evidence of connective tissue fibroblasts,
MSCs, osteoblasts, etc. Additionally, the tissue sections need to be more closely examined for the
presence of an immune response at an earlier time (such as three days post surgery), also via
rigorous IHC staining for neutrophils, foreign body giant cells, and plasma cells. Currently, the
presence of an inflammatory response appears small (if one is present at all), and the fused
constructs show little evidence of significant immune cell recruitment. Moreover, a rigorous
quantification of the capillaries present in the implants should be compared to the average VAF
data: because the resolution of the US probe only allows detection of vessels greater than 30 μm
in diameter, it’s possible the US analysis could have missed smaller feeder vessels present
throughout the implants. Greater characterization of the immune response earlier in vivo may
elucidate the mechanism of why vascularization decreases between weeks 1-2, and whether the
higher VAFs observed at week 1 were due to inflammation. Overall, the fused construct design
contained a high cell density early at 1 week in vivo for all constructs containing allogenic cells,
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and these cells deposited tissue matrix that could be a precursor to bone, if the implants were
harvested later than 4 weeks post-surgery. This study shows that the OP/Accessory cell
microcapsule system could serve as a viable platform to promote well-vascularized bone
regeneration, and further optimization of the implants with respect to accessory and OP cell density
is warranted.
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CHAPTER 7: CONCLUSION
The C4S/HAP/Chitosan microcapsules supported the osteogenesis of encapsulated MSCs,
and the expected peaks in ALP and BSP expression were observed, consistent with MSC
differentiation to an osteoblast phenotype. The differentiating MSCs actively mineralized the
microcapsule interior, and deposited mineral around the HAP microgranules and microcapsule
membrane. Moreover, the MSCs remained viable in the microcapsule cultures for 28 days, and the
presence of mineral did not significantly inhibit viability; however, the mineral buildup may have
inhibited nutrient flow through the microcapsule membrane, inhibiting proliferation. It is possible
that the mineralization of the microcapsule membrane could inhibit cell proliferation in vivo;
however, the hypoxic cues that would result, along with other chemotactic cues present in vivo,
could cause encapsulated cells to migrate and escape the diffusion-limited microcapsule interior.
Additionally, lysozymes present in vivo could degrade the microcapsule membrane, removing one
barrier to nutrient diffusion as the system mineralizes. Results suggests that microcapsules
containing MSCs or OPs would rapidly mineralize in vivo, in the growth factor and signaling
milieu of a bone defect site, and regenerate bone.
Fused microcapsule constructs could be fabricated from mineralized microcapsules, and
the presence and architecture of cell-deposited mineral greatly influenced the overall mechanical
properties of the constructs. Moreover, it was evident that the organization of the mineral within
the microcapsules, and not just the amount of mineral, significantly influenced the mechanical
properties of fused constructs. This study suggests that an effective strategy to improve the
toughness of fused constructs could involve directly mineralizing the membranes of microcapsules
containing HAP microgranules, potentially tethering mineralizing enzymes to the polymer
components of the microcapsule.
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Accessory cells significantly improved the vascularization of fused constructs in vivo 4
weeks post-surgery, compared to acellular constructs, and constructs containing only OPs. There
was no statistical difference between the effects of MSCs and EPs on fused construct
vascularization in our system, indicating that the extra step of differentiating MSCs to EPs is
unnecessary, although a longer in vivo implant period should be examined to confirm this.
Additionally, all fused constructs with cells exhibited significantly higher tissue growth between
the microcapsules, and dense collagen deposition indicating a precursor to bone tissue, compared
to the relatively sparse tissue in acellular implants. More work is required to characterize any hard
tissue that was deposited in the implants in vivo: this requires conducting hard tissue histology on
undecalcified implants, and specialized sectioning tools.
Other groups have attempted similar strategies to generate modular bone regeneration
systems. An early modular system involved the culture of human amniotic MSCs on porous
dextran beads, to generate a 2 x 1 cm (diameter x height) cylinder from the cell laden modules
[104]. The amniotic MSCs were cultured on the dextran beads as modular units 700-800 μm in
diameter, in a bioreactor system to rapidly proliferate and generate matrix prior to fusion into a
construct. The bioreactor-based cell expansion is a useful strategy to increase the cell-density of
the modular units, and this strategy could be employed with the microcapsule system described
here. Another attempt at modular bone regeneration involved the fabrication of collagen/chitosan
hydrogel beads, encapsulating MSCs [103]. These hydrogel beads could be fabricated quickly
using an emulsion process that preserved cell viability and osteogenic capability, and could be
extruded as a paste to facilitate minimally invasive delivery in vivo. Neither of these modular
systems had their mechanical properties characterized, however, so it’s difficult to determine how
they would recapitulate the mechanical properties of native bone in vivo.
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As the importance of designing vascularization strategies into bone regeneration systems
becomes clearer with more data, other research groups are developing modular systems that
include a vascular cell component. The field of modular tissue engineering is relatively new, and
vascularized bone modular regeneration even more recent, so relatively few studies have been
published in this area. Two recent studies of note utilize HUVECs as the vascular cell component,
and involve either 1) co-culturing HUVECs and MSCs on gelatin microcarriers [139], or 2) coculturing HUVECs and MG-63 cells (an immortalized osteoblast cell line) on gelatin
microcarriers, and fusing these cell-laden microcarriers into larger constructs [140]. Both of these
studies use HUVECs as a model vascular-cell to study the effects co-culturing vascular-osteogenic
cells in vitro: specifically, both papers pay particular attention to the effects of vascular-cells on
MSC or MG-63 osteogenesis (expression of osteogenic markers), and endothelial markers (CD31,
VE-Cadherin, vWF) overtime in culture. Both studies show that the HUVECs and osteogenic cells
could maintain their expression of tissue-specific markers over a 28-day culture period. These two
studies are good models of how both cell types respond in a co-culture with vascular and
osteogenic cells on a common biomaterial (gelatin). The study using MG-63 cell line could not be
translated to the clinic, unless another non-immortalized cell type was used. Neither study
discussed the performance of their vascularized modular system in a non-immunocompromised
mammal, which was one of the features of the study detailed in this dissertation. Additionally, the
vascular cell-type used in this dissertation can be easily generated in the clinic: MSCs are easily
harvested from a patient’s bone marrow, and the differentiation medium is relatively inexpensive.
The project featured in this dissertation extends the vascularized modular bone regeneration idea
to generated tissue in an immunocompetent mammal (rat) using clinically relevant cell sources
(OPs and EPs generated from MSCs), helping extend the field beyond model cell types.
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The design for a bone regeneration platform presented here shows how modular tissue
engineering principles can help engineer tissue with multicellular organization that enhances
vascularization in vivo, and a unique configuration of cell and ceramic materials that produces
mechanically tough tissue. The overall design has shown the ability to rapidly regenerate tissue in
a subcutaneous model, and initial results indicate the presence of bone matrix precursor in the
subcutaneous implants. The modular bone regeneration platform is a promising system that
warrants further development and optimization for future clinical applications involving hard
tissue regeneration.
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CHAPTER 8: FUTURE WORK
The results of this project indicate that the modular bone regeneration platform shows
promise to regenerate vascularized bone; however, more work is required to fully characterize the
tissue developed in vivo in the microcapsule constructs. The US data showing enhanced
vascularization in constructs with EPs/MSCs is impressive, but the limited resolution of the US
probe means that microcapillaries (diameter < 30 μm) were not counted in the average VAF data.
The tissue explants will be further analyzed for the presence of blood vessels of all sizes via
immunohistochemical (IHC) staining of CD31+ cells (endothelial cells) in paraffin sections.
Additionally, the presence of an inflammatory response in the tissue sections should be evaluated
via IHC staining of Ly-6 proteins (neutrophils), CD38 (plasma B cells), and CD68 (macrophages).
Another in vivo study should be conducted, this time will all exogenous cells labelled with noncanonical amino acids (distinguishing them from native cells) to determine whether these cells
participate directly in tissue regeneration, or if they evacuate the implant but induce native cell
infiltration via cell homing [141]. Essentially, implanted cells could be fed a diet of methionine
derivatives that cells metabolize into peptides that would normally contain methionine: these
“labelled” cells are then implanted in the microcapsule system in vivo. The methionine derivatives
are easily reacted with fluorophore-conjugated azides, enabling the implanted cells left in the
implant to be identified. Ideally, the derivatized methionine labelling is less invasive than other
methods, such as transfection for green fluorescent protein (GFP) expression. Finally,
undecalcified tissue implants will be sectioned using specialized hard-tissue sectioning equipment,
and the presence of mineral deposited in vivo in the subcutaneous implants will be evaluated to
discern whether the accessory cells enhanced mineralization of the microcapsule system.
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Alternative microcapsule fusion strategies need to be developed, to broaden the application
of the microcapsules to minimally invasive surgery (arthroscopic injection into bone defect), and
3D printing of tissue constructs, among other applications. The GAG/chitosan complex
microcapsule fusion protocol utilized to fuse microcapsules in this study requires a mold and
perfusion to fuse microcapsules, inhibiting the use to the microcapsules for arthroscopic injection
cases. A better microcapsule fusion system would involve the deposition of either a photoactive
polymer layer (such as methacrylated chitosan [142], methacrylated hyaluronan [143] or
methacrylated collagen [144]), or crosslinking enzyme layer (tyramine/horseradish peroxidase
[145]) on the exterior of the microcapsules. The photoactive/enzyme layers would be engineered
in such a way that microcapsules could be injected along with a catalyst (photoinitiator/enzyme
cofactor, respectively) that would cause capsules to adhere to one-another after extrusion. A
microcapsule fusion strategy that does not require a mold and polymer perfusion will significantly
enhance the applications of the microcapsules to regenerate tissue of complex shapes in situ, or
via 3D printing equipment.
The increase in mechanical properties of the fused microcapsule constructs due to
mineralization was impressive, but the mechanics still fall short of native bone. The relatively low
mechanical properties stem from 1) the weak microcapsule membrane, and 2) the significant void
space in the microcapsule interior, even when the microcapsules are partially filled with HAP. The
targeted mineralization of the microcapsule membranes by tethering ALP to one of the polymers
involved in microcapsule fabrication was discussed in the Chapter 7. Another strategy to improve
fused construct mechanical properties involves decreasing the non-mineral void space in the
microcapsule interior. A microcapsule formulation utilizing hyaluronan (HA), C4S and chitosan
to form the microcapsules can contract when the microcapsules contain an internal collagen gel
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and MSCs (fig 8.1). Essentially, the collagen gel becomes incorporated into the microcapsule
membrane, and MSCs are able to contract the gel to collapse the membrane [146]. It’s likely fused
constructs created form these collapsed capsules would have significantly better mechanical
properties than the C4S/chitosan microcapsules presented in this study.

Fig 8.1: Microcapsules with internal collagen gel and hyaluronan in microcapsule membrane can be contracted
with encapsulated MSCs in culture. Credit: Patrick Michael Erickson, Undergraduate in Tissue Engineering Lab.

The microcapsule design is inherently tunable, and the microcapsule properties can be
augmented by using different polymers for the polyelectrolyte membrane, incorporating different
ECM gels/microcarriers in the microcapsule interior, and adjusting the types and density of cells
in and attached to the microcapsules. The ability to substantially customize the GAG/chitosan
microcapsules for various applications makes these a useful tool that tissue engineers can use to
generate tissue with complexity that better mimics physiological tissue. These microcapsules were
used to generate bone, but another tissue engineer may use a similar design to generate tissue of
greater complexity, and eventually a world without implantable organ shortages.
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The gold standard for bone regeneration requires harvesting a piece of healthy bone from
the patient through a painful procedure, but this piece of autologous bone graft contains the bone
and endothelial cells required to rapidly regenerate bone in a defect. We have developed a modular
bone regeneration platform, composed of mesenchymal stem cells (MSCs) and hydroxyapatite
(HAP) microgranules encapsulated in microcapsules, to replace autologous graft harvesting. The
microcapsules are composed of a polyelectrolyte membrane formed by the ionic-complex reaction
between chondroitin 4-sulfate (C4S) and chitosan. The specific aims of this thesis were to 1)
examine the ability of C4S/HAP/chitosan microcapsules to support osteogenesis of encapsulated
MSCs, 2) characterize how microcapsule mineralization influences mechanical properties of fused
microcapsule constructs, and 3) analyze how endothelial progenitors (EPs) attached to the
microcapsule exterior influence the vascularization of fused constructs in vivo.
The microcapsules supported the osteogenesis of encapsulated MSCs, and an in vitro
analysis showed enhanced alkaline phosphatase (ALP), osteocalcin and osteopontin expression.
Furthermore, biochemical assays and Scanning Electron Microscopy (SEM) confirmed that
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osteoinduced MSCs deposited a calcium and collagen rich mineralized extracellular matrix (ECM)
in the microcapsule interior after 4 weeks osteoinduction in vitro. Hydrated, compressive
mechanical testing demonstrated that fused constructs composed of mineralized microcapsules
exhibited significant resistance to compression, up to a yield strength of 10.4 + 4.4 MPa. Analysis
of the yield strength and elastic moduli demonstrated that the compressive mechanical properties
depend primarily on active mineralization of the microcapsules by differentiating MSCs, and to a
lesser extent on HAP microgranules. Micro computed tomography (MicroCT) and SEM analysis
of fused constructs showed that the organization and architecture of the mineral within the
microcapsules determined the overall mechanical properties of fused constructs. EPs or MSCs
were cultured on the microcapsule exterior, and fused constructs were fabricated with these
microcapsules, so that the EPs/MSCs were localized to the intercapsule pore space. Fused
constructs containing EPs or MSCs in the pore space were evaluated for their vascularization and
tissue regeneration in a rat subcutaneous model. Doppler Ultrasound (US) analysis of blood flow
through implanted constructs revealed that microcapsules with EPs or MSCs in the construct pore
space had enhanced vascularization 4 weeks post-surgery, compared to fused constructs with only
encapsulated

osteoprogenitors

and

acellular

constructs.

Results

indicate

that

the

C4S/HAP/Chitosan microcapsules can function as the basis of a bone regeneration platform, and
that culture of either EPs or undifferentiated MSCs can enhance the vascularization of fused
microcapsule constructs in vivo. Our studies warrant further development and optimization of the
C4S/HAP/Chitosan microcapsules as a replacement for painful autologous bone graft harvesting.
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